Studies of hypoxia response and regulation of hypoxia-inducible factor HIF-1 in Caenorhabditis elegans by Shen, Chuan
Retrospective Theses and Dissertations Iowa State University Capstones, Theses andDissertations
2006
Studies of hypoxia response and regulation of
hypoxia-inducible factor HIF-1 in Caenorhabditis
elegans
Chuan Shen
Iowa State University
Follow this and additional works at: https://lib.dr.iastate.edu/rtd
Part of the Genetics Commons, and the Molecular Biology Commons
This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University
Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University
Digital Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
Shen, Chuan, "Studies of hypoxia response and regulation of hypoxia-inducible factor HIF-1 in Caenorhabditis elegans " (2006).
Retrospective Theses and Dissertations. 3022.
https://lib.dr.iastate.edu/rtd/3022
Studies of hypoxia response and regulation of hypoxia-inducible factor HIF-1 
in Caenorhabditis elegans 
by 
Chuan S hen 
A dissertation submitted to the graduate faculty 
in partial fulfillment of the requirements for the degree of 
DOCTOR OF PHILOSOPHY 
Major: Toxicology 
Program of Study Committee: 
Jo Anne Powell-Coffman, Major Professor 
Marit Nilsen-Hamilton 
Jeffrey Beetham 
Drena Dobbs 
Clark Coffman 
Iowa State University 
Ames, Iowa 
2006 
Copyright © Chuan Shen, 2006. All rights reserved. 
UMI Number: 3229124 
INFORMATION TO USERS 
The quality of this reproduction is dependent upon the quality of the copy 
submitted. Broken or indistinct print, colored or poor quality illustrations and 
photographs, print bleed-through, substandard margins, and improper 
alignment can adversely affect reproduction. 
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if unauthorized 
copyright material had to be removed, a note will indicate the deletion. 
UMI 
UMI Microform 3229124 
Copyright 2006 by ProQuest Information and Learning Company. 
All rights reserved. This microform edition is protected against 
unauthorized copying under Title 17, United States Code. 
ProQuest Information and Learning Company 
300 North Zeeb Road 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346 
ii 
Graduate College 
Iowa State University 
This is to certify that the doctoral dissertation of 
Chuan Shen 
has met the dissertation requirements of Iowa State University 
Major Professor 
'or the Major Prog
Signature was redacted for privacy.
Signature was redacted for privacy.
iii 
TABLE OF CONTENTS 
CHAPTER 1 GENERAL INTRODUCTION 1 
Literature Review 2 
Dissertation Organization 22 
References 24 
CHAPTER 2 ROLES OF THE HIF-1 HYPOXIA-INDUCIBLE FACTOR DURING 
HYPOXIA RESPONSE IN CAENORHABDITIS ELEGANS 34 
Abstract 34 
Introduction 35 
Experimental Procedures 37 
Results 40 
Discussion 48 
Acknowledgements 53 
References 53 
CHAPTER 3 THE RHY-1 INTEGRAL MEMBRANE PROTEIN SUPPRESSES 
HIF-1 HYPOXIA-INDUCIBLE FACTOR ACTIVITY IN CAENORHABDITIS 
ELEGANS IN A NEGATIVE FEEDBACK LOOP THAT DOES NOT 
INCLUDE VHL-1 70 
Abstract 70 
Introduction 71 
Experimental Procedures 74 
Results 78 
Discussion 85 
Acknowledgements 91 
References 91 
CHAPTER 4 GENERAL CONCLUSIONS 107 
Summary 107 
References 115 
ACKNOWLEDGEMENTS 118 
1 
CHAPTER 1 GENERAL INTRODUCTION 
All aerobic organisms require molecular oxygen to generate metabolic energy for 
normal growth and survival. During evolution, multi-cellular organisms have developed and 
refined complex networks for adaptation to hypoxic environments at both systemic and 
cellular levels (1,2). Adaptation to hypoxia largely results from changes in the activity and 
expression of key proteins. These include proteins involved in increasing oxygen delivery to 
hypoxic tissues and proteins that facilitate glycolysis for anaerobic metabolism (2). The 
mammalian transcription factor hypoxia-inducible factor (HIF) is a master regulator of 
oxygen homeostasis. More than 100 target genes of HIF mediate broad systemic and local 
responses to hypoxia, including angiogenesis/vascular remodeling, erythropoiesis, glucose 
transport, glycolytic metabolism, and cell proliferation (3). Many human diseases such as 
myocardial ischemia, stroke, cancer, and chronic lung disease cause hypoxic stress, and HIF 
is a critical mediator for pathophysiological responses to hypoxia (4). Elucidating cellular 
and molecular mechanisms underlying regulation of HIF activity may enable novel 
therapeutic approaches (5). The C. elegans hif-1 gene is orthologous to mammalian HIF-
alpha gene, and C. elegans has proven to be a powerful system for the study of hypoxia-
inducible factor regulation and function (6). In this dissertation, I studied the role of HIF-1 in 
hypoxia response and initiated genetic studies to identify HIF-1 regulators in C. elegans. I 
demonstrate that C. elegans hif-1 regulates the majority of early transcriptional responses to 
hypoxia. My studies also provide clear evidence for HIF-1-independent pathways for 
adaptation to oxygen deprivation (7). Finally, I discovered a novel membrane-bound protein 
that regulates the activity of C. elegans HIF-1 in a potential negative feedback loop. 
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Literature Review 
Hypoxia-inducible factors 
Discovery and molecular cloning of HIF-la and |3 subunits 
HIF-1 was first identified as the transcriptional complex that increased erythropoietin 
(EPO) in response to hypoxia. In 1992, Semenza and Wang discovered that a nuclear factor 
interacted with the 3' hypoxia response element (HRE) of EPO in an oxygen-dependent 
manner (8). They named this DNA-binding complex as "hypoxia-inducible factor 1" or 
"HIF-1". Later studies showed that HIF-1 DNA binding activity was presented in various 
non-erythropoietin-producing cell lines under hypoxic conditions (9), indicating that HIF-1 
might have a general role in activating hypoxia-response gene expression. By using 
biochemical purification, Wang and Semenza revealed that HIF-1 was a heterodimeric factor 
consisting of a 120KDa a-subunit and a 91-94 KDa 3-subunit (10). Then, they partially 
sequenced the purified protein fragments, and they cloned HIF-la cDNA by comparison 
with sequence databases (11). Wang and Semenza's studies showed that both HIF-1 subunits 
contain basic helix-loop-helix (bHLH) and PER-ARNT-SIM (PAS) domains. While HIF-la 
subunit was a novel protein, HIF-1(3 had been identified previously as aryl hydrocarbon 
receptor nuclear translocator (ARNT), which dimerized with the aryl hydrocarbon receptor 
after its activation by aryl hydrocarbons such as dioxin (12). Later on, HIF-la cDNA was 
independently cloned by others during studies of ARNT (13) and the transcriptional 
coactivator p300/CBP (14). 
Structure and function of HIF-1 
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HIF-1 is heterodimeric protein consisting of HIF-la and HIF-ip subunits (10). While 
HIF-ip is constitutively expressed as a subunit of several different heterodimers, expression 
of HIF-la is tightly regulated by oxygen concentration (15). Both subunits contain a basic 
helix-loop-helix (bHLH) motif and two Per-ARNT-Sim (PAS) domains designated PAS-A 
and PAS-B (11) (Figure 1). The basic domain is essential for DNA binding, and the HLH-
PAS domain is required for dimerization of HIF-la and HIF-1(3 (16). HIF-1 heterodimer 
binds to the consensus DNA sequences 5-RCGTG-3% which are located in the DNA major 
groove (9). 
HIF-la contains an oxygen-dependent degradation (ODD) domain, which is 
responsible for oxygen-mediated regulation of HIF-la protein stability (17) (Figure 1). 
When oxygen levels are sufficiently high, the conserved proline residues P402 and P564 
within the ODD domain are modified by HIF prolyl hydroxylases (Figure 1), which trigger 
VHL tumor suppressor protein-mediated ubiquitination and subsequent proteosomal 
degradation (18). The well elucidated HIF/HIF prolyl hydroxylase/pVHL-mediated pathway 
will be further described later in this chapter. A recent study showed that the HIF-la ODD 
domain can bind to tumor suppressor p53 under physiological conditions, indicating the 
existence of new potential regulatory mechanisms (19). 
HIF-la also contains two transactivation domains, which are required for the 
transcriptional regulation of HIF-1 targets (16). The N-terminal TAD is overlapped with the 
ODD domain (Figure 1). Both TADs recruit transcriptional co-activators including 
CBP/p300, Ref-1, SRC-1 and TIF-2 (14). It has been found that cysteine 800 in HIF-la is 
critical for the interaction of HIF-la with the coactivator p300/CBP (20). HIF-1 (3 also 
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Figure 1. Protein domains of HIF-1 a and HIF-ip. 
Functional domains and binding domains with co-
factors are shown, bHLH, basic helix-loop-helix; ODD, 
oxygen-dependent degradation domain; NTAD and 
CTAD, N- and C-terminal transactivation domain; NLS, 
nuclear localisation signal; PAS, Per-ARNT-Sim. Amino 
acids which are important for HIF-1 a expression and 
activity are indicated. 
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contains a TAD domain. However, the function of this domain on HIF-l's transcriptional 
activity is unclear. Recruitment of p300/CBP to HIF-1 TAD domains is essential for 
regulating HIF-1 transcriptional activity. I will discuss these regulatory mechanisms later in 
the chapter. 
HIF-la contains two nuclear localization signals (NLS). One is located at the N-
terminus within the bHLH domain, and one is located within the C-terminal region of HIF-
la (21) (Figure 1). Studies showed that the C-terminal NLS was functional, and a missense 
mutation within this region could prevent the nuclear localization of GFP-HIF-la under 
hypoxia (21). Later studies indicated that the functional C-terminal NLS of HIF-la is a 
bipartite-type NLS, which is characterized by two sets of adjacent basic residues separated by 
a spacer of about 10 amino acids (22). The nuclear translocation of HIF-la is independent of 
the presence of HIF-ip (23). However, heterodimerization is required for nuclear 
stabilization of both subunits (23). HIF-ip also contains a NLS signal at the N-terminus of 
the protein, which causes HEF-ip to be expressed constitutively in the nucleus (Figure 1). 
Additional mammalian HIFs 
In addition to HIF-la, there are two other members in this family in mammals: HIF-
2a and HIF-3a. HIF-2a is also known as endothelial PAS domain protein 1 (EPAS1), HIF-
la-like factor (HLF), HIF-related factor (HRF), and member of PAS super-family 2 (MOP2) 
(24). HIF-2a has high similarity with HIF-la in the main functional domains. Like HIF-la, 
it exhibits oxygen-dependent regulation, dimerization with ARNT, DNA 
recognization/binding, and activation of hypoxia-mediated gene expression (25). Little is 
known about the regulation and activity of HIF-3a. A recent study indicated that HIF-3a is 
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also regulated by ubiquitination and proteasome-mediated pathway for degradation (26). One 
of the splice variants of HIF-3a, named IPAS (inhibitory PAS domain protein), was found to 
inhibit the transcriptional activity of HIF-la by competing for binding with HIF-1(3 (27). 
While HIF-la is expressed ubiquitously, both HIF-2a and HIF-3a are expressed in 
more restricted, but partially overlapping, cell types. Studies of HIF-la and HIF-2a have 
shown that the functions of these two proteins are not redundant. HIF-la knockout mouse 
embryos died around midegestation with neural tube defects, cardiovascular malformations, 
and marked cell death within the cephalic mesenchyme (28). Loss of function of HIF-2a 
caused embryonic lethality in mouse with distinct defects in the cardiovascular system, such 
as defects in catecholamine homeostasis (29) or aberrant vascular remodeling (30). Recent 
studies also have shown that HIF-la and HEF-2a regulate overlapping but non-identical 
target genes even in same cell types (31). Raval et al. (2005) reported that in renal carcinoma 
cells, the protumorigenie genes encoding cyclin Dl, transforming growth factor alpha, and 
vascular endothelial growth factor were specifically regulated by HEF-2a, but not HIF-la. 
Also, the proapoptotic gene encoding BNip3 responded positively to HIF-la and negatively 
to HIF-2a in renal carcinoma cells. Other studies showed that only overexpression of HIF-2a, 
but not HIF-la, promotes growth of renal carcinoma cells (32). 
Roles of HIF-1 in human cancers and therapeutic applications for targeting HIF-1 
Under hypoxia, HIF-la dimerizes with HIF-1(3 and the heterodimer binds to core 
binding site 5'-RCGTG-3' to activate transcription of target genes. The number of target 
genes activated by HIF-1 continues to increase, and so far, more than 100 genes have been 
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shown to be putative HIF-1 target genes in mammals. The HIF-1 target genes encode protein 
products which are involved in angiogenesis/vascular remodeling, energy metabolism, 
erythropoiesis, cell proliferation and viability, which makes HIF-1 a major mediator of 
physiological and pathophysiological responses to hypoxia. HIF-1 has been shown to be 
involved in many hypoxia characterized human diseases such as ischemic cardiovascular 
disorders, pulmonary hypertension, and cancers (Reviewed in (4)). The role of HIF-1 in 
tumor progression and therapeutic strategies for targeting HIF-1 will be described here. 
Role of HIF-1 in tumor development 
In solid tumors, rapid cell proliferation, severe structural abnormalities of tumor 
microvessels, and disturbed microcirculation lead to a hypoxic microenvironment (33). Low 
oxygen partial pressures in tumor cells correlates with resistance to radiotherapy and 
chemotherapy (34). A critical molecular mechanism by which tumor cells adapt to hypoxic 
microenviroments is to increase the level of HIF-1. Several lines of evidence reveal the 
essential role of HIF-1 in tumor progression. First, HIF-la is overexpressed in a variety of 
human cancers, including escophageal, brain, breast, lung, ovarian, cervical, and colon 
cancers. In early-stage cervical carcinoma, HIF-la overexpression is correlated with patient 
mortality (35). In oropharyngeal squamous cell carcinoma, the degree of HIF-la expression 
is correlated with both radiation resistance and patient mortality (36). Second, HIF-1 
activates the expression of target genes such as angiogenic signaling genes and glycolytic 
enzyme genes which allow the tumor to adapt to hypoxia. Angiogenesis, the process by 
which new blood vessels form from the existing vasculature, is critical for the growth of 
tumors. New vascularization provides fresh nutrients and oxygen to rapidly proliferating 
tumor cells (37). Up-regulation of VEGF is HIF-1 dependent (38), resulting in activation of 
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the angiogenic switch and induction of neovascularization at the early stage of tumorigenesis 
(39). The ability to induce angiogenesis is associated with the rapid tumor growth and 
metastasis (40). Also, tumor cells are generally characterized by low oxygen supply and high 
glucose consumption rate, and anaerobic glycolysis becomes the major way for ATP 
generation (25). HIF-1 promotes anaerobic glycolysis in tumor cells by activation of 
metabolic enzymes such as aldolase A, phosphoglycerate kinase 1, and pyruvate kinase (41). 
Third, tumor hypoxia renders a physiological stress that activates cell death pathways (42). 
Meanwhile, hypoxia selects death-resistant cells, which in turn contribute to cancer 
progression (43). HIF-1 can mediate hypoxic control of cell death in tumor growth. 
Embryonic stem (ES) cells with inactive HIF-la genes (HIF-la v") have decreased hypoxia-
induced apoptosis (44). Induction of the cell death factors such as BNIP3 and NIX in human 
tumors is HIF-1-dependent (45). IAP-2, an apoptosis inhibiting protein mediated by HIF-1, 
has been shown to be strikingly induced by severe hypoxia in various types of cells (46). 
Fourth, It has been reported that HIF-la expression and activity were affected by the tumor 
suppressor gene p53. The p53 gene was found mutated in over 50 % of human cancers (47), 
indicating its critical role in tumor suppression. Several studies have shown direct interaction 
between HIF-la and p53 (48). Recent studies also further defined the direct interaction 
between HIF-la ODD domain and p53 by using biophysical techniques (19). The interaction 
of these two proteins supports the previous studies indicating that p53 can repress HIF-la 
stimulated signaling by competing for binding to p300 (49), and can facilitate Mdm2-
dependent degradation of HIF-la (50). 
Therapeutic application for targeting HIF-1 
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The essential roles of HIF-1 for the adaptation to hypoxic tumor microenvironments 
point to a promising therapeutic approach. Currently, a variety of anticancer drugs have been 
reported to inhibit HIF-1 (Reviewed in (51)). In 1999, the Giovanni Melillo lab at the 
National Cancer Institute began to screen for HIF-1 inhibitors. They successfully found that 
the camptothecins, well known topoisomerase I inhibitors, could inhibit HIF-1 by a 
topoisomerase I-dependent inhibition of translation (52). Currently, topotecan, an FDA-
approved semisynthetic camptothecin analogue, is in phase I human trials for treatment of 
human cancers characterized by high HIF-1 levels such as ovarian cancer and small cell lung 
cancer (53). Another promising HIF-1 inhibitor to enter the clinic is PX-478. PX-478 
increases ubiquitination and degradation of HIF-la by an undefined mechanism. PX-478 
shows potent antitumor effects with decreased expression of HIF-1 target genes such as 
VEGF and glucose transporter-1, with tumor regression and long-term growth delay in mice 
(54). There are also a number of other potential HIF-1 inhibitors, including Radicicol (Hsp-
90 inhibitor that reduces HIF-la DNA binding activity), FK228 (Histone deacetylase 
inhibitor for that decreases HIF-1 transcription), and Rapamycin (PI-3-kinase pathway 
inhibitor that reduces HIF-1 translation) (Reviewed in (53)). For the future, it is essential to 
elucidate the functions of these small inhibitors on HIF-1 expression or transactivating 
activity in tumors in vivo. 
Pharmacological manipulation of HIF-la has promising clinical applications in 
hypoxia characterized diseases. Fully understanding of regulation of HIF-1 expression and 
activity would provide foundational knowledge for its therapeutic targeting. 
Regulation of HIF stability by the PHD/pVHL pathway 
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pVHL tumor suppressor protein and ubiqutination of HIF-1 
Von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome characterized by 
central nervous system and retinal hemangioblastomas, clear cell renal carcinoma, and 
pheochromocytomas. It was first described in the medical literature in 1894 by Treacher 
Collins. A decade later, Eugene von Hippel recorded observations of blood vessel tumors of 
the retina in patients. Later, the Swedish pathologist Arvid Lindau reported that such patients 
were at high risk of developing blood vessel tumors of the brain and spinal cord, known as 
hemangioblastomas. In memory of these founders, the disease was called "von Hipple-
Lindau disease" in 1936. A variety of other tumors have been associated with VHL disease 
including visceral cysts, clear-cell renal carcinomas, pheochromocytomas, endolymphatic-
sac tumors and islet-cell tumors of the pancreas (Reviewed in (55)). 
The VHL gene was mapped on chromosome 3 in 1988 by Seizinger et al (56). 
Individuals with VHL disease are VHL heterozygotes with one wild-type allele and one 
defective allele (56). The VHL gene encodes two proteins (pVHL) due to alternative 
translation initiation, and both isoforms retain tumor suppressor activity (57). Biochemical 
studies revealed that pVHL was a component of a multiprotein complex including elongin B, 
elongin C, Cul2, and Rbxl, which resemble so called SCF ubiquitin ligases (58). SCF 
complexes target specific proteins for degradation by a post-translational modification called 
polyubiquitylation (59). The potential function of pVHL promoting polyubiquitination was 
supported by the fact that purified pVHL contained an ubiquitin ligase activity (60). 
The inactivation of pVHL in tumors always causes the overexpression of hypoxia-
responsive genes such as vascular endothelial growth factor (VEGF) (61). In 1999, Maxwell 
et al showed that HIF-la was not degraded in the cells lacking pVHL, and pVHL and HIF-
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la can bind to each other (62). Very soon after Maxwell's observation, pVHL protein was 
found to bind directly to the ODD domain of HIF-la via its beta-domain, which results in the 
polyubiqutination and subsequently proteasomal degradation of HIF-la in the presence of 
oxygen (63) (Figure 2). Thus, these studies proved the mechanistic explanation for over-
expression of hypoxia-response mRNAs in tumors lacking of pVHL. 
Prolyl hydroxylation and discovery of EGL-9/PHD enzymes 
Studies showed that the HIF-la ODD domain was sufficient to confer instability of 
HIF-la in the presence of oxygen (64). In 2001, three groups independently showed that an 
oxygen-dependent posttranslational modification was critical for interaction between pVHL 
and HIF-la ODD domain, and for the ubiqutination and proteasomal degradation of HIF-la 
under normoxic conditions (65-67). Their studies showed that the hydroxylation of 
evolutionary conserved proline residues at the motif LXXLAP within the HIF-la ODD 
domain resulted in binding of pVHL to HIF-la (Figure 2). 
Soon after these great findings, another big breakthrough was made by Ratcliffe's 
group at Oxford. They successfully identified HEF prolyl hydroxylases which are responsible 
for hydroxylation of the conserved proline residues in HIF-la ODD by studying egl-9 gene 
in the nematode C. elegans (68) (Figure 2). 
First, Ratcliffe and colleagues demonstrated hydroxylation of the LXXLAP motif in C. 
elegans HIF-1 allows direct binding of VHL-1, the ortholog of VHL. Then they isolated 
mutant worms carrying a deletion in the vhl-1 gene, and they found that the VHL-1-deficient 
worms expressed high level of HIF-1 at both normoxia and hypoxia. Secondly, they 
identified the enzyme that hydroxylates HIF-1 ODD by assaying HIF-1 protein levels in a 
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Figure 2. regulation of HIF stability by the PHD/pVHL pathway. 
Oxygen concentration determines the rate at which HIF-1 a is 
subject to prolyl hydroxylation by HIF prolyl hydroxylases (PHD). 
Prolyl hydroxylation is required for the interaction of HIF-1 a with 
VHL which recruits elongins B and C, Cullin 2 (CUL2), and RBX1 
(R) to form an E3 ubiquitin-protein ligase complex, resulting in 
HIF-1 a degradation. Under hypoxic conditions, HIF-1 « escapes 
prolyl hydroxylation, ubiquitination and degradation. HIF-1 P 
dimerizes with HIF-1 a . The HIF-1 heterodimer binds to hypoxia 
response elements containing the core recognition sequence 5'-
RCGTG-3' and recruits coactivator (Coact) molecules resulting in 
increased gene expressions for hypoxia adaptation. 
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series of mutant strains. They found that animals carrying loss-of-function mutations in the 
egl-9 gene failed to downregulate HIF-1 expression in normoxic conditions. Additional 
experiments demonstrated that the EGL-9 protein acted directly on HIF-1 to hydroxylate the 
proline in the LXXLAP motif in vitro. C. elegans gene egl-9 was originally identified from 
the genetic screen for egg-laying-defective phenotypes (69). Later studies showed that egl-9 
encode a protein belonging to the iron and 2-oxoglutarate-dependent dioxygenase 
superfamily (70). Finally, through secondary structure prediction algorithms, Ratcliffe and 
colleagues identified mammalian homologs of EGL-9 in the same dioxygenase superfamily 
(termed as prolyl hydroxylase domain (PHD) 1, PHD2, & PHD3) and demonstrated that the 
mammalian PHDs hydroxylate human HIF-la or HCF-2a in vitro. Soon after Ratcliffe and 
colleagues' studies, mammalian HIF prolyl hydroxylases were also identified by other groups 
using biochemical technologies, which were named as EglN or HPH proteins (71,72). 
Regulation of PHD enzymes 
Since the discovery that the HIF/PHD/pVHL pathway was the central mechanism for 
regulating HIF-la protein degradation, extensive studies have showed that factors 
regulations of PHD enzymes have essential roles for hypoxia signaling in organisms 
(Reviewed in (73)). Major known regulators of PHD enzymes will be summarized here. 
PHD enzymes use oxygen as their co-substrate. Studies using VHL capture by a short 
HIF-la polypeptide as a measure of hydroxylation have demonstrated that PHD enzyme 
activity was greatly affected by oxygen concentration in vitro (68). Studies also confirmed 
the direct incorporation of oxygen into the HIF-la substrate by monitoring the incorporation 
of 180 into the sites of prolyl hydroxylation by mass spectrometry (74). In keeping with this, 
by using 14CÛ2 release from labeled 20G, researchers measured PHD enzymes apparent Km 
values for molecular oxygen in the range 230-250 pM (75). Nitric oxide (NO) also has been 
shown to cause accumulation of HIF under normoxic conditions (76,77). One explanation is 
the ability of NO to inhibit 20G-dependent oxygenases by acting as an analogue of 
molecular oxygen (78). 
Studies also have shown that multiple factors affect the availability of other co-
substrates such as Fe (II) and 2-oxoglutarate (20G), thereby regulating the activities of PHD 
enzymes. Studies showed molecules that reduce or inhibit Fe(II), such as iron chelators and 
metals such as Co(II), Ni(II), and Mn(II), can enhance HIF-lot levels (68). It remains to be 
elucidated whether changes in cellular iron availability play a physiological role in the 
regulation of PHD enzymes. Several studies have demonstrated that cellular level of reactive 
oxygen species (ROS) has roles in regulating HIF-1 activity (Reviewed in (79)). A recent 
study provided the evidence that junD reduces ROS levels as part of a defense against 
oxidative stress (80). PHD2 activity was found to be reduced in junD deficient cells, and the 
potential mechanism involved Fenton's reaction: the conversion of Fe(II) to Fe(III) by 
elevated ROS levels (80). The citric cycle intermediate 20G is also a co-substrate for PHD 
enzymes. Levels of other citric cycle intermediates such as succinate or fumarate have been 
shown to affect PHD enzymes activities, as they are competitive inhibitors of 20G (81). 
Molecules that inhibit PHDs would be predicted to be tumorigenic. Indeed, certain tumors 
have defects in succinate dehydrogenase (subunits B, C or D), such as hereditary paraglioma. 
Other tumors have defects in fumarate hydratase, such as leiomyomata of the skin, uterine 
fibroids and papillary renal cell carcinoma. In these cancers, levels of succinate and fumarate 
are increased, and this appears to inhibit the PHD enzymes activities as competitive 
inhibitors of 20G (81). 
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PHD associated proteins could also play roles in the regulation of these enzymes. The 
ring-finger E3 ligases Siahla/2 have been found to associate with PHD3 in 
immunoprecipitates (82). In Siahla/2 deficient cells PHD3 is highly expressed, and HIF-1 is 
downregulated. Also, in Siah2 deficient mice, hypoxia-induced gene expression is defective. 
Using the yeast two-hybrid system, the protein OS9 has been found to interact with PHD2 
(83). Interaction with OS9 enhanced the activity of PHD2 and downregulated the HIF-la 
protein level. In a recent study, the tumor suppressor ING4 was found to interact with PHD2, 
and unexpectedly, the interaction did not affect HIF-la stability, but HIF-la transactivation 
(84). The underlying mechanism is unclear. 
Both PHD2 and PHD3 have been shown to be transcriptionally regulated by HIF, 
forming a negative feedback loop (85). The induction of PHD2 and PHD3 in hypoxia 
contributes to the enhanced rates of HIF degradation during reoxygenation (86). Studies also 
showed that PHD2 is the most abundant PHD enzyme under normoxia, and it plays 
important roles for setting normoxic levels of HIF-la (87). PHD3 plays important roles for 
setting hypoxic levels of HIF-la (87). These studies further indicate that the oxygen level 
determines the function of PHD enzymes. 
Other regulatory mechanisms of HIF-1 activity 
Organisms also use a number of other hypoxia-dependent and -independent strategies 
to regulate HIF-1 activity at multiple levels, including translation, protein stabilization, 
posttranslational modifications, nuclear localization, DNA binding capacity, and 
transcriptional co-activator recruitment (Reviewed in (25)). Some mechanisms related to 
HIF-1 expression level and activity will be summarized here. 
HIF-la protein level 
The well-characterized VHL-mediated ubiquitin-proteasome pathway as described 
above plays essential roles for HIF-1 degradation. Several post-translational modifications 
have been shown to regulate the interaction between pVHL and HIF-la, including 
acetylation and phosphorylation. Acetyltransferase ARD1 aceylates lysine residue in the 
HIF-la ODD domain, which results in the enhancement of the interaction between HIF-la 
and E3-ligase pVHL (88). Researchers have had difficulty repeating this observation, so this 
finding remains controversial. In human pancreatic cancer cells, p38 MAPK-mediated 
phosphorylation of HIF-la contributed to the inhibition of HIF-la and pVHL interaction 
(89). 
Other potential VHL-independent degradation pathways maybe involved in HIF-1 
protein stability (90). The nuclear expression of forkhead transcription factor F0X04 has 
been shown to suppress the hypoxia response by down-regulation of HIF-1 a protein level. 
F0X04 inhibition of HIF-1 appears to involve in a proteasome-dependent degradation 
pathway which is independent of VHL-mediated function (90). A recent study showed that 
hi stone deacetylase inhibitors produced a dose- and time-dependent inhibition of 
accumulated HIF-la levels (91). Histone deacetylase inhibitors-induced degradation of HIF-
la was reported to be ubiquitination independent and mediated by a proteasome system 
which was independent of VHL function. These studies further suggested that histone 
deacetylse 6 (HDAC6) mediated hyperacetylation of Hsp90, which affected HIF-la 
stabilization. Another recently published study showed the existence of transcription-
dependent degradation of HIF-la in several mammalian cell lines in a PHD/VHL pathway 
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independent mechanism (92). Demidenko et al. showed that inhibition of transcription using 
transcription inhibitors had no effect on HIF-la induction under normoxia, but caused super-
induction of HIF-la under hypoxia, indicating that accumulation of HIF-la under hypoxia 
could transcriptionally activates a feedback loop for the degradation of HIF-la. 
There is growing evidence that multiple cellular signaling pathways can lead to the 
induction of HIF-1 in oxygen-independent manner (Reviewed in (3)). HER2 activation 
increases the rate of HIF-la protein synthesis via phosphatidylinositol 3-kinase (PI3K) and 
the downstream serine-threonine kinases AKT (protein kinase B) and mTOR (mammalian 
target of rapamycin) (93). IGF-1 enhanced the HIF-la protein synthesis, and this was 
dependent upon both the PI3K and MAPK pathways (94). Current models suggest that 
mTOR phosphorylates and activates the translational regulatory protein p70 S6 kinase, which 
phosphorylates the 40S ribosomal protein S6, resulting in the elevated HIF-la protein 
translation. 
Transcriptional co-activator recruitment 
The HIF-1 complex recruits a number of coactivators, including p300/CBP, Ref-1, 
Jabl, SCR-1 and TIF2, to transactivate the expression of a multitude of targets genes 
(Reviewed in (25)). The regulation of the interaction between p300/CBP and HIF-la has 
great impact for HIF-1 transactivation under hypoxia. Oxygen-dependent asparagine 
hydroxylation has a critical role in this. Under normoxia, an asparagine residue (Asn-803) in 
the CTAD domain of HIF-la is hydroxylated by an asparaginyl hydroxylase enzyme called 
FIH (factor-inhibiting HIF). Like the PHDs, FIH belongs to the oxygen and iron dependent 
dioxygenase family (74). The hydroxylation prevents recruitment of the coactivator 
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CBP/p300, thereby inhibiting transcriptional activity of HIF-1 (95). Under hypoxia, the 
enzymatic activity of FIH is inhibited, which enables the recruitment of CBP/p300 to HIF-1. 
There are also number of other mechanisms involved in the interaction of p300/CBP and 
HIF-la. Hypoxia-induced CITED2/p35srj and CITED4 proteins have shown to bind to 
CBP/p300, and they down-regulate HIF-1 transactivation by blocking the interaction 
between HIF-la and p300 (96). The phosphorylation of p300 by MAPK increased the 
interaction between the HIF-la C-TAD and p300 (97). The p53 tumor suppressor could 
repress HIF-la activity by competing co-activator p300 binding (49). 
Important unanswered questions about HIF regulation 
The HIF hydroxylases appear to function as oxygen sensors, as the PHD and FIH 
enzymes require molecular oxygen. Important questions remaining to be answered include: 1) 
Are these potential oxygen sensors involved in other non-HIF-mediated hypoxia sensitive 
signaling pathways? 2) Recent studies showed the potential roles of PHDs on HIF-la 
transactivation, in addition to HIF-la protein stabilization. What are the molecular 
mechanisms underlying the VHL-independent functions of PHD enzymes? 3) The relation of 
in vitro characteristics of these PHD enzymes with their physiological functions in intact 
organisms needs the further elucidation. It's important to answer the question of whether 
pharmacological inhibition of the HIF hydroxylases is an effective therapeutic strategy in 
ischaemic/hypoxic disease. 
In addition to HIF hydroxylases-regulated oxygen sensing machinery, there are many 
other signaling processes such as phosphorylation involved in HIF-1-dependent gene 
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expression. This suggests the existence of additional pathways that signal changes in the 
cellular oxygen concentration. The big questions raised are: 1) Are there other oxygen 
sensors regulating HIF-1 activity, and what are these potential oxygen sensors? 2) How are 
these multiple regulatory mechanisms integrated to generate the appropriate physiological 
response, and how do these pathways impact the development of HIF-targeted therapeutic 
strategies in clinic? 
VHL-dependent ubiquitination and proteasomal degradation is a central mechanism 
for regulation of HIF-la protein stability. However, there are several reports showing the 
existence of VHL- independent degradation pathways. The underlying mechanisms are less 
understood. The questions raised are: 1) What are the important proteins mediating 
degradation of HIF-1 in a VHL-independent manner? 2) Is there condition specificity 
(normoxia or hypoxia) and/or tissue specificity for these degradation pathways, and what is 
the relationship with the VHL-mediated pathway? 
Hypoxia response in C. elegans 
The genetic model system C. elegans 
The nematode C. elegans is a powerful animal model system for the dissection of 
evolutionary conserved signaling pathways. C. elegans are small (~1 mm in length as 
adults), and they can be cultured on agar plates with a bacterial food source. There are two 
sexes, self-fertilizing hermaphrodites and males, and the generation time is less than 4 days at 
20°C. The simplicity and experimental convenience of C. elegans make it an attractive model 
organism for genetic analyses. The sequence of the ~108 bp genome was completed in 1998, 
revealing approximately 19,000 genes (98). Recently the discovery of microRNAs has 
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increased this estimate (99). Large scale studies, such as double-stranded RNA interference 
library and full-genome microarrays, are available to worm researchers, and are 
tremendously helpful to studying gene functions in C. elegans. 
In the wild, C. elegans inhabits the soil, where it can encounter hypoxic 
microenvironments. C. elegans is able to maintain a near normal metabolic rate at 
environmental oxygen concentrations as low as 2%. In 0.5% or 1% oxygen, the animals 
must decrease oxygen consumption, but they continue to develop and reproduce (100). C. 
elegans does not have a complex circulatory system. Any cell in the organism is only a few 
cell widths from the outer surface of the worm or the intestinal lumen (101), and oxygen 
delivery is thought to be accomplished by diffusion. Thus, individual cells must sense and 
adapt to local environmental oxygen levels. Recent discoveries have revealed that the 
molecular mechanisms that govern transcriptional responses to hypoxia are, at least in part, 
conserved between C. elegans and humans (6). 
Evolutionarily conserved hypoxia signaling pathway in C. elegans 
The C. elegans hif-1 gene is orthologous to mammalian HIF alpha subunits (6). Like 
its mammalian cognates, C. elegans HIF-1 protein is induced by hypoxia and is rapidly 
degraded upon re-oxygenation (6,68). hif-1 mRNA levels are not dramatically affected by 
oxygen concentration (6). Under conditions in which C. elegans HIF-1 is stable, it binds 
AHA-1, the ortholog of mammalian ARNT/HIF-beta (102) to form a complex that can bind 
DNA sequences containing the hypoxic regulatory element (6). Both HIF-1 and AHA-1 are 
expressed in most, if not all, cells, as assayed by a hif-1:GFP reporter gene and AHA-1-
specific antibodies. As described above, HIF-1, VHL-1 and EGL-9 appear to be part of an 
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evolutionary conserved regulatory network that senses hypoxia and implements appropriate 
transcriptional changes. 
Hif-1 is required for adaptation to hypoxia 
The hif-1 (ia04) mutation is predicted to be a strong loss-of-function allele. It deletes 
exons 2-4 of hif-1, and it introduces an early translational stop codon to the most abundant 
forms of hif-1 mRNA (6). Animals that are homozygous for the hif-1 mutation exhibit no 
visible defects under standard laboratory conditions. However, hif-1-defective animals are 
unable to adapt to 0.5% or 1% oxygen. While wild type animals survive and reproduce in 1% 
oxygen, 66% of hif-1-defective animals do not survive embryogenesis in these conditions, 
and an additional 9% die during larval development (6,103). In a recent genetic screen, I 
discovered a new hif-1 (ia07) allele, in which the point mutation C824T causes a premature 
stop codon. hif-l(ia07) mutants expresse a truncated HIF-1 protein without the conserved 
ODD domain and putative TAD domain. 67% of hif-l(ia07) worms do not survive 
embryogenesis under 0.5% oxygen condition (unpublished data). As described in Chapter 2, 
genome-wide studies have shown that hif-1 regulates the majority of early transcriptional 
responses to hypoxia in C. elegans (7). Certain HIF-1 targets genes also play critical roles 
for survival in hypoxic condition (7). 
The high degree of conservation of the HIF- 1/EGL-9/VHL-1 system indicates that 
genetic studies in C. elegans should be highly informative in studying the upstream 
regulators of HIF-1, and potentially the downstream physiological functions of HIF-1. This 
knowledge would have foundational roles for developing therapeutic strategies, such as drugs 
inhibiting activation of HIF-1 in tumor growth. Recently, the studies and clinic trails suggest 
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that low molecular weight inhibitors of EGL-9/HIF prolyl hydroxylase are promising 
pharmacological agents (72,104-106). 
Dissertation Organization 
Our research group and others have reported that C. elegans hif-1 and HIF-1 signaling 
pathways are evolutionary conserved (6,68). In this dissertation, I examine the hif-1-
dependent/independent gene expression changes during hypoxia response in worms using 
genome-wide DNA microarray analyses. Also I identify a novel membrane regulator of HIF-
1, which suppresses HIF-1 activity by a potential VHL-1 -independent feedback loop. 
In Chapter 1, literature related to the study is reviewed. Major topics include: (i) 
Description of mammalian hypoxia-inducible factors, including the historical discovery and 
molecular cloning of HIF-1 alpha and beta subunits, structure and function of HIF-1, and 
additional HIFs. (ii) Involvement of HIF-1 in human cancers and therapeutic applications for 
HIF-1 inhibitors, (iii) Regulation of HIF stability by PHD/pVHL pathway, including 
historical overview of pVHL discovery, prolyl hydroxylation and EGL-9 discovery. Current 
studies involved in regulations of HIF prolyl hydroxylases are also summarized, (iv) Other 
regulatory mechanisms of HIF-1 activity, with emphasis on regulations of HIF-la protein 
stability and transcriptional co-activator recruitment, (v) Hypoxia response in C. elegans. I 
introduce the genetic model organism C. elegans, and describe evidence that hif-1 is 
evolutionary required for hypoxia response in worms. 
Chapter 2 is a copy of a research paper published in The Journal of Biological 
Chemistry, 2005, 280(21): 20580-20588. The title is "Roles of the HIF-1 hypoxia-inducible 
factor during hypoxia response in Caenorhabditis elegans". Main findings include: (i) 
Genome-wide DNA microarray analyses identified hypoxia responsive genes induced in both 
hif-1 -dependent and ^^-independent manners in worms. The majority of hypoxia regulated 
gene expression changes were dependent upon hif-1 function, (ii) Description of functions of 
hypoxia-responsive genes with emphasis on discussion of genes encoding metabolic enzymes, 
signaling molecules, extracellular matrices proteins, ubiquitin ligase, transcriptional factors 
and heatshock proteins, (iii) Identification of essential functions for individual hif-1-
dependent genes. In particular, gene phy-2 is required for hypoxia survival, (iv) Molecular 
links between hypoxia response and dauer formation, (v) VHL-1 regulates HIF-1 function 
and also has HIF-1 independent functions. Other researchers were also involved in this study. 
As principal investigator, Jo Anne Powell-Coffman contributed to experimental design and 
manuscript editing. Min Jiang and Stuart Kim at Stanford University performed microarray 
hybridizations. Daniel Nettleton at Iowa State University analyzed the microarray data by 
writing statistical programs. Qunfeng Dong at Iowa State University helped generate Figure 
2, which shows genomic distribution of hypoxia-responsive genes. 
Chapter 3 is a copy of a manuscript to be submitted for publication. The title is "The 
RHY-1 integral membrane protein suppresses HIF-1 hypoxia-inducible factor activity in 
Caenorhabditis elegans in a negative feedback loop that does not include VHL-1". The 
major findings includes: (i) Generation of a visual assay system for studying HIF-1 activity. 
By using the promoter of HIF-1 target gene nhr-57 fused to GFP as a reporter, I could detect 
the enhanced expression of the reporter under hypoxic condition and VHL-1 loss-of-function 
background, (ii) EGL-9 has VHL-1-independent function in which it regulates HIF-1 
transcriptional activity, rather than HIF-1 protein stabilization, (iii) Identification of rhy-1, 
which encodes a member of acyltransferase family proteins and functions as a novel negative 
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regulator of HIF-1. My studies show that rhy-1 functions independent of VHL-1 to inhibit 
HIF-1 activity. My genetic data also suggest that RHY-1 and EGL-9 could function at the 
same pathway, (iv) Study of RHY-1 expression pattern. My data show that RHY-1 is 
expressed mainly in intestine and head sensory neurons in worms, as well as weaker 
expression in hypodermis, socket cells, and vuval muscles. For this work, former lab member 
Kelly Gillette and Mae Young isolated and mapped rhy-1 ia38 allele. Zhiyong Shao, a PhD 
graduate student in the lab, generated the rhy-1 promoter fused with W07A12.6 coding 
sequence construct. He also did W07A12.6 RNAi experiment. Jo Anne Powell-Coffman was 
the principal investigator. 
In Chapter 4,1 summarize the major findings in my thesis research, with emphasis on 
impact and contribution to the field. In brief, I show that C. elegans hif-1 regulates the 
majority of hypoxia-induced gene expression changes, and certain HIF-1 target genes are 
critical for hypoxia survival. My study also clearly indicates the existence of hif-1-
independent pathway(s) for hypoxia adaptation. I show that EGL-9 has functions regulating 
HIF-1 transcriptional activity, rather than HIF-1 protein stabilization in worms. I identify 
gene rhy-1 as a novel negative regulator of HIF-1 by suppression of HIF-1 transcriptional 
activity in a VHL-1-independent mechanism. 
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Abstract 
The human hypoxia-inducible transcription factor HIF-1 is a critical regulator of 
cellular and systemic responses to low oxygen levels. When oxygen levels are high, the HIF-
la subunit is hydroxylated and is targeted for degradation by the von Hippel-Lindau tumor 
suppressor protein (pVHL). This regulatory pathway is evolutionary conserved, and the 
Caenorhabditis elegans hif-1 and vhl-1 genes encode homologs of the HEF-la subunit and 
VHL. To understand and describe more fully the molecular basis for hypoxia response in this 
important genetic model system, we compared hypoxia-induced changes in mRNA 
expression in wild-type, hif-1 -deficient, and vhl-1 -deficient C. elegans using whole genome 
microarrays. These studies identified 110 hypoxia-regulated gene expression changes, 63 of 
which require hif-1 function. Mutation of vhl-1 abrogates most hif-1-dependent changes in 
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mRNA expression. Genes regulated by C. elegans hif-1 have predicted functions in signal 
transduction, metabolism, transport, and extracellular matrix remodeling. We examined the in 
vivo requirement for 16 HIF-1 target genes and discovered that the phy-2 prolyl 4-
hydroxylase a subunit is critical for survival in hypoxic conditions. Some HIF-1 target genes 
negatively regulate formation of stress-resistant dauer larvae. The microarray data presented 
herein also provide clear evidence for an HIF-1-independent pathway for hypoxia response, 
and this pathway regulates the expression of multiple heat shock proteins and several 
transcription factors. 
Introduction 
During development, homeostasis, or disease states, cellular oxygen levels are often 
insufficient to meet physiological demands, and this condition is termed hypoxia. 
Mammalian cells respond to hypoxia by implementing changes in gene expression to 
increase anaerobic energy production, protect cells from stress, regulate cell survival, and 
increase local angiogenesis. The requisite changes in gene expression are largely controlled 
by the hypoxia-inducible factor 1 (HIF-1) transcription factor (1, 2). 
HIF-1 is a heterodimeric DNA-binding complex, and both subunits are members of 
the family of transcription factors containing basic-helix-loop-helix and Per-ARNT-Sim 
domains. The HDF-ip subunit is also termed ARNT (aryl hydrocarbon receptor nuclear 
translocator). Although ARNT can dimerize with other transcription factors, HJF-lcc is 
apparently dedicated to a hypoxia response (3-5). When oxygen levels are high, specific 
proline residues of HIF-la are hydroxylated by oxygen-dependent enzymes belonging to the 
EGL-9/PH superfamily of 2-oxoglutarate-dependent dioxygenases (6, 7). Proline 
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hydroxylation in the conserved LXXLAP motif in HIF-la increases its affinity for the von 
Hippel-Lindau tumor suppressor protein (VHL), which is part of an E3 ubiquitin-ligase 
complex that targets proteins for proteasomal degradation. Thus, when VHL is disabled by 
mutation, HIF-1 is expressed at constitutively high levels (8). 
Cells utilize multiple strategies to regulate HIF-la activity. HIF-la is modified post-
translationally by hydroxylation, phosphorylation, and acetylation (7, 9, 10). Oxygen-
dependent hydroxylation of the HIF-la C terminus inhibits binding to the coactivator 
CBP/p300 (11, 12). Growth factor stimulation may modulate HIF-la transcriptional activity 
via small GTPases and mitogen-activated protein kinase cascades (13, 14). The availability of 
interacting proteins, such as transcriptional coactivators, also influences HIF-1 function. 
Important questions remain. What other oxygen-sensing molecules control cellular hypoxia 
response? What are the most important VHL-independent mechanisms for regulating HIF-1 
activity? What fraction of the transcriptional response to hypoxia is controlled by HIF-1? 
Caenorhabditis elegans has recently proven to be an important model system for 
studying hypoxia response. The C. elegans homolog of the HIF-la subunit is hif-1, and the 
HIF-1 /EGL-9/VHL pathway is evolutionary conserved (6, 15). C. elegans carrying 
deletions in the hif-1 gene are apparently healthy in standard culture conditions, but they 
exhibit high levels of lethality in 0.5 or 1% oxygen (15, 16). To identify genes regulated by 
HIF-1 during response to hypoxia and to determine what fraction of hypoxia-induced gene 
expression changes is dependent upon hif-1, we conducted genomewide studies of hypoxia-
induced changes in mRNA expression in wild-type, A//-/-deficient, and v/j/-7-deficient C. 
elegans. These studies demonstrate that C. elegans hif-1 regulates the majority of early 
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transcriptional responses to hypoxia and provide clear evidence for HIF-1-independent 
pathways for adaptation to oxygen deprivation. 
Experimental Procedures 
C. elegans culture, microarray experiments, and data analysis 
C. elegans were cultured using standard procedures on NGM plates with an 
Escherichia coli food source (17). For hypoxia treatments, plates containing synchronized 
third stage larvae were placed either in room air (normoxia control) or a sealed plexiglass 
chamber with constant gas flow. Compressed air and pure nitrogen were mixed to achieve the 
appropriate oxygen concentration, as assayed by an oxygen sensor (15). We were most 
interested in the earliest hif-1-dependent and /izj-i-independent responses to hypoxia. 
Therefore, we assayed mRNA expression at the earliest time point at which the F22B5.4 
transcript was consistently induced (4 h at 21 °C in 0.1% oxygen). At the time that this study 
was conducted, F22B5.4 was the only C. elegans transcript shown to be induced by hypoxia. 
The F22B5.4 putative 5'-regulatory sequences contain multiple elements similar to the 
mammalian hypoxia response element (HRE), the DNA binding site for the HIF-1 
transcriptional complex, and F22B5.4 is expressed at high levels in egl-9 mutants (6). These 
data suggested that F22B5.4 might be a direct target for C. elegans HIF-1. For the microarray 
experiments, three strains were assayed: wild-type N2, hif-1 (ia04), and vhl-1 (oklôl). 
Worms were incubated for 4 h in 21% oxygen or 0.1% oxygen at 21 °C. Animals were 
quickly harvested in ice-cold M9 buffer, and poly(A) RNA was isolated using established 
procedures. No more than 3 min elapsed between the removal of plates from the hypoxic 
chamber and the addition of TRIzol. 
The microarray hybridizations were performed by Min Jiang in the laboratory of 
Stuart K. Kim at Stanford University (18). cDNA from animals incubated in 21% O2 
(normoxia) was labeled with Cy5, and cDNA from hypoxia-treated worms was labeled with 
Cy3. There were 18 mRNA samples: (two oxygen concentrations x three genotypes x three 
independent experiments). Each hybridization compared expression in normoxia versus 
hypoxia for one genotype, and nine experiments were performed. The raw data and the 
normalized data are available at the Stanford Microarray Data base. The following criteria 
were used to filter the data: FLAG = 0; failed = 0; red and green fluorescence intensity at 
least 2-fold above background. We averaged the log] values (hypoxia net 
intensity/normalized normoxia net intensity) from each experiment. Student's t test p values 
were determined with the averages for each strain. 
To identify putative regulatory elements in M/-i-dependent genes, we used the motif-
finding program at bioprospector.stanford.edu (BioProspector). We searched for DNA 
sequences that were overrepresented in the 18 genes most strongly induced by hypoxia in 
Table I relative to the 47 hif-1 -independent genes. Sequences 200-2,000 bp upstream from 
each putative translational start were used for this analysis. Gene cluster analyses were 
performed using tools available at PlantGDB (19). 
Viability assays 
To create DNA constructs for bacteria-mediated RNAi, cDNAs provided by Yuji 
Kohara were subcloned into the L4440 double-T7 vector (20). When cDNAs were not 
available, coding sequences were PGR amplified using primers designed by Valerie Reinke 
(21). The resulting constructs were transformed into E. coli strain HT115 (DE3) (20). RNAi 
39 
analyses were performed as described previously (22). Additionally, embryonic and larval 
viability was assayed in the following mutant strains: hif-1 (ia04), cam-1 (gml22), egl-9 
(sa307), fmo-12 (ok299), fmo-14 (ok294), inx-2 (ok376), /?/ry-2 (okl77), and vab-1 (e2). 
Assays for viability at 21 or 0.5% O2 at 21 °C were performed as described previously (16). 
Three independent experiments were conducted for each condition, and Student's t test was 
used to judge whether averaged values differed significantly. 
RNA blots 
Total RNAs were isolated from synchronized L3 stage wild-type (Bristol strain N2) 
worms, hif-1 (ia04) mutants, vhl-1 (oklôl) mutants, and hif-1 (ia04) vhl-1 (pkl61) double 
mutants that had been incubated for 4 h in normoxia or hypoxia (0.5% O2). The RNA 
samples were fractionated via agarose-formaldehyde gel electrophoresis and transferred to 
nylon membranes. DNA probes for RNA blot analyses were amplified using published 
primers (21). Hybridizations were performed using [a-32P]dCTP-labeled probes, and signals 
were detected and quantified using a phosphorimager. 
GFP reporter analysis 
To generate the phy-2:GFP construct pSHOl, DNA was PGR amplified using the 
primers Phy2PF2 (PstI) 5 '-ggcgctgcag AG ACT AT AGTCT AT AGCT GA A A ACG and 
Phy2PR2 (BamHI) 5'-gcgggatccACTGCTCTCATTCTGAAAGACAAATC. The PCR 
product includes the phy-2 sequence from -1715 bp to +11 bp relative to the translational 
start site (23). These regulatory sequences were cloned into GFP vector pPD95.75 (provided 
by A. Fire, Carnegie Institution of Washington). To create transgenic animals, the DNA was 
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coinjected with the pRF-4 rol-6 marker (24). Five independent transgenic lines were 
examined. 
Results 
The primary goals of these studies were to identify hypoxia-induced gene expression 
changes in C. elegans and to determine which of these responses to hypoxia were regulated 
by hif-1. Toward these aims, we analyzed mRNA expression patterns in synchronized 
populations of wild-type worms that were cultured in standard laboratory conditions 
(normoxia) or in hypoxia. We also assayed mRNA from two mutant strains: (a) animals 
carrying the strong loss-of-function mutation in hif-1 and (b) C. elegans that carry a deletion 
in vhl-1 and express the HIF-1 protein at constitutively high levels. RNA was isolated from 
three independent experiments for each experimental condition (three genotypes; normoxia 
versus hypoxia). mRNAs were hybridized to whole genome microarrays that contained 
probes for 17,817 predicted genes (94% of the genome). To identify hypoxia-induced gene 
expression changes in wild-type worms, we used two criteria. First, we identified genes that 
exhibited a significant difference in mRNA levels in hypoxia versus normoxia as judged by 
Student's t test, p value <0.05. Second, we focused on genes that showed an average hypoxia-
induced difference in mRNA expression greater than or equal to 2-fold. 110 genes met both 
of these criteria. To determine which of these gene expression changes were dependent upon 
hif-1 function, we examined the data from hif-1 (ia04) mutants. 63 of the 110 hypoxia-
responsive genes were not significantly regulated by hypoxia in hif-1 (ia04) mutants (p value 
> 0.05), and they are listed in Table I. In this article, we will refer to this class of genes as 
"hif-1-dependent." The 47 genes listed in Table II were expressed at significantly higher or 
41 
lower levels in hypoxia in hif-1-deficient animals (p value < 0.05; Table II), and we will refer 
to them as "^^-independent" genes. In most cases, hypoxia caused increased gene 
expression, but 6 of the /zz/-./-dependent genes and 3 of the hif-1-independent genes were 
down-regulated by hypoxia. A total of 654 genes met less stringent criteria for hypoxia-
responsive genes (1.5-fold average difference between hypoxia and normoxia treatments;p < 
0.05), and they are listed in the supplemental data at 
http://www.ibc.org/cgi/content/full/M501894200/DC1. To validate further the microarray 
data and to compare directly the expression of certain genes in the presence or absence of hif-
1 and vhl-1 function, we analyzed the expression of a subset of the hypoxia-induced genes on 
RNA blots. C. elegans hypoxia has been defined as oxygen concentrations between 0.1 and 
2% (25, 26). To confirm that the gene expression changes detected by our microarray 
analyses were induced by another oxygen concentration in this range, we repeated the 
experiments using 0.5% oxygen. We tested eight of the hif-1 -dependent genes. One of these 
genes, F57B9.1, was not expressed at levels detectable by RNA blot analysis. The other seven 
genes were (a) induced by hypoxia in wild-type animals; (b) expressed at lower levels in hif-
1  - d e f e c t i v e  m u t a n t s ;  ( c )  e x p r e s s e d  a t  h i g h e r  l e v e l s  i n  a n i m a l s  l a c k i n g  v h l - 1  f u n c t i o n ;  a n d  ( d )  
expressed at low levels in double mutants, consistent with VHL-1 acting as a regulator of 
HIF-1 (Fig. 1 A). Genes were chosen for RNA blot analysis based on signal intensity, level of 
differential expression, and, in some cases, predicted function. The seven hif-1-dependent 
genes tested (and their predicted functions) were fino-12 (flavin-containing monooxygenase), 
F22B5.4 (unknown function), W07A12.7 (acyltransferase), phy-2 (prolyl 4-hydroxylase a 
subunit), nhr-57 (nuclear hormone receptor), egl-9 (2-oxoglutarate-dependent oxygenase), 
and K10H10.2 (cysteine synthase). We assayed four of the hif-1 -independent genes listed in 
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Table II by RNA blots. They were F26A3.4 (phosphatase), C12C8.1 (Hsp70), F44E5.5 
(Hsp70), and R166.5 (serine/threonine kinase). All four were induced by hypoxia in wild-
type animals and in mutants lacking hif-1 or vhl-1 function (Fig. IB). 
Although the hypoxia-responsive genes are located on all six chromosomes, 40% of 
the hif-1 -dependent genes are on chromosome II, and many of these are found in clusters (Fig. 
2). Three genes (F45D11.1, F45D11.2, and F45D 11.16) are within 50 kb of each other at the 
left arm of II. Multiple small clusters are located at the center of the chromosome, and a 10-
kb domain on the right arm of II contains two hif-1-dependent genes (K10H10.2 and 
K10H10.4). With one exception (two hif-1-independent genes on chromosome III), hypoxia-
responsive genes on the other four autosomes or on the X are not clustered. 
We anticipated that some of the hif-1-dependent genes would be direct targets of the 
HIF-1 transcriptional complex. The mammalian HIF-la and |3 subunits form a heterodimer 
and bind to specific DNA sequences (HREs) that contain the sequence 5-RCGTG (27). A 
survey of the sequences 200-2,000 bp 5' to the predicted translational start sites shows that 
the motif 5-TACGTG is present in 46% of the hif-1-dependent genes (Table I). In 
comparison, this putative HRE is present in only 23% of hif-1 -independent genes (Table II). 
Functions of hypoxia-responsive genes 
Metabolic enzymes are prevalent in both Table I and Table II. For example, pyc-1 
encodes pyruvate carboxylase, a key enzyme in gluconeogenesis, and it was induced by 
hypoxia in a ^^-independent manner (2.2-fold; p value 0.038). Some glycolytic enzymes 
were induced at lower levels. F14B4.2 hexokinase, R05F9.6 phosphoglucomutase, T21B 10.2 
enolase, and R11F4.1 glycerol kinase are expressed 1.4—1.9-fold higher levels in hypoxia 
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relative to normoxia (p < 0.05). Two enzymes predicted to facilitate the conversion of fatty 
acids to sugars were also induced by hypoxia. C05E4.9/gei-7 (isocitrate lyase) and 
F54H12.1 /aco-2 (aconitate hydratase) were induced 2.8-fold and 1.8-fold, respectively (Table 
II and supplemental data at http://www.jbc.org/cgi/content/full/M501894200/DCl). 
Predicted signaling molecules are another major functional class in both Tables I and 
II. For example, F26A3.4, a hif-1-independent gene, encodes a protein-tyrosine phosphatase 
similar to the mammalian mitogen-activated protein kinase phosphatase 6. Additionally, cam-
1, a receptor tyrosine kinase orthologous to human ROR1 and ROR2, and the dpf-6 
dipeptidyl peptidase, which is predicted to hydrolyze peptide ligands, are both hif-1-
dependent genes. 
Hypoxia appeared to induce changes in extracellular matrices. The phy-2 prolyl 4-
hydroxylase a subunit gene and the bli-3 NADPH oxidase were induced by hypoxia, and 
both have central roles in collagen synthesis (28, 29) (Tables I and II, respectively). Genes 
encoding three predicted extracellular molecules with lectin domains (C31G12.2, F35D 11.10, 
and F47C12.2) and one predicted chitin-binding protein (K04H4.2) also exhibited hypoxia-
responsive mRNA expression (Tables I and II). 
Interestingly, we found that egl-9 mRNA levels were induced by hypoxia in a hif-1 -
dependent manner (Fig. 1A). The egl-9 gene encodes a 2-oxoglutarate-dependent oxygenase, 
and it is thought to be the sole HIF prolyl hydroxylase (PHD) in C. elegans. Using oxygen as 
a substrate, EGL-9 hydroxylates HIF-1 in the conserved LXXLAP motif. This modification 
increases the affinity of HIF-1 for the VHL-1 E3 ligase, which targets HIF-1 for proteosomal 
degradation. In eg/-9-deficient animals, HIF-1 protein is expressed at constitutively high 
levels (6). 
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hif-1 function was required for hypoxia-dependent regulation of smg-2, efk-1, and a 
predicted ubiquitin ligase (C34D4.14) (Table I). These gene products are predicted to act 
post-transcriptionally to change cellular proteosomes. smg-2 is required for the degradation of 
mRNAs containing early nonsense codons. The gene efk-1 is strongly induced by hypoxia, 
and it encodes a calcium/calmodulin-dependent kinase with homology to human elongation 
factor-2 kinase (eEF-2 kinase). eEF-2 kinase decreases protein synthesis by phosphorylating 
and inactivating elongation factor 2. Mammals activate eEF-2 kinase activity upon oxygen 
deprivation (30). Thus, modulation of protein synthesis via eEF-2 kinase may be an important 
aspect of adaptation to changing oxygen levels. 
Interestingly, many of the hif-1-independent genes listed in Table II are transcription 
factors and heat shock proteins. 17% (8/47) of ^«/-/-independent genes are predicted 
transcriptional regulators. In comparison, only 5% (3/63) of the hif-1-dependent genes are 
likely transcription factors, and this is similar to the prevalence of predicted transcription 
factors in the complete genome (31). The C. elegans heat shock protein genes C12C8.1, 
F08H9.4, F44E5.5, and F44E5.4 were all induced 4.5-5.6-fold by hypoxia, and induction of 
these heat shock proteins does not require hif-1 function (Table II). 
Many other C. elegans researchers have performed microarray experiments to identify 
genes that were expressed differentially during specific developmental stages or in response 
to diverse environmental stresses. Computational analyses of these data have resulted in the 
identification of "mountains" of coexpressed genes (32). We note that 43% of the hif-1-
independent (20/47) and 13% of the /n/-7-dependent genes (8/63) are in "mountain 1," a 
1,818-gene cluster enriched in genes with neuronal or muscle function. 
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Essential functions for individual hif-1-dependent genes 
Mutants lacking hif-1 function exhibit a much higher level of embryonic and larval 
lethality in hypoxic conditions compared with wild-type C. elegans. Thus, we anticipated that 
certain individual HIF-1 target genes might also be critical for survival in hypoxia. To test 
this hypothesis, we used existing mutant strains or RNAi to examine the requirement for 16 
individual AzfJ-dependent genes in hypoxia. We tested 7 strains carrying loss-of-function 
mutations in hif-1-dependent genes, and 5 of the strains exhibited a statistically significant 
decrease in embryonic or larval viability in 0.5% oxygen relative to wild-type animals. As 
shown in Fig. 3, animals carrying loss-of-function mutations in fmo-12, fmo-14, vab-1, or 
inx-2 were slightly more vulnerable to hypoxic stress than were wild-type worms. 
The most dramatic hypoxia-dependent phenotypes were evident in animals carrying a 
strong loss-of-function mutation in the phy-2 prolyl 4-hydroxylase a subunit. Prior studies 
have shown that the phy-2 prolyl 4-hydroxylase a subunit has a central role in collagen 
synthesis, and genetic analyses have shown that in normal culture conditions the 
developmental functions of phy-2 could also be provided by dpy-18 (23, 33). As shown in Fig. 
3, only 22.3% of phy-2 (okl77) mutant animals successfully completed embryogenesis in 
0.5% oxygen. 97% of wild-type animals and 58.2% of hif-1 (ia04) embryos hatched in the 
same conditions. Animals lacking dpy-18 function were relatively healthy in hypoxia (94% 
hatch; n = 91). These data show that dpy-18 cannot completely compensate for loss of phy-2 
function when oxygen is limiting. 
When phy-2 (okl77) mutants were allowed to complete embryogenesis in normal 
culture conditions and then transferred to a hypoxic chamber (0.5% oxygen) to complete 
development, 79% were sterile as adults (n = 38). This was unexpected because expression of 
a phy-2:lacZ transgene has been reported to be predominantly hypodermal (23). To examine 
the phy-2 expression pattern in live animals, we constructed a phy-2:GFP reporter, phy-
2:GFP was strongly expressed in the hypodermis, excretory cell, and spermatheca (Fig. 4). 
These data are consistent with the hypothesis that collagen synthesis in the spermatheca is 
important to fertility and embryonic viability. 
We used RNAi to examine the requirement for an additional 9 hif-1 -dependent genes. 
These assays required culturing the animals on plates containing isopropyl l-thio-(3-D-
galactopyranoside and tetracycline, and worms grown on control bacteria in these conditions 
showed increased sensitivity to hypoxia (Fig. 5). Worms treated with RNAi for the genes 
F22B5.4 (unknown function), nhr-57 (nuclear hormone receptor), K10H10.2 (cysteine 
synthase), or M05D6.5 (protein containing a hypoxia-inducible domain) exhibited higher 
levels of embryonic lethality in 0.5% oxygen (Fig. 5). 
Molecular links between hypoxia response and dauer formation 
Some of the genes induced by hypoxia also regulate entry into the dauer phase, an 
alternative larval stage characterized by low metabolic rate and resistance to environmental 
stress. Mutations that favor dauer formation generally also confer longevity and resistance to 
certain environmental stresses. At sufficiently high temperatures, oxygen deprivation is toxic 
to wild-type C. elegans, and this experimental regimen has been termed hypoxic death. 
Interestingly, specific mutations in the daf-2 insulin-like growth factor receptor gene confer 
resistance to hypoxic death (34). Loss-of-function mutations in daf-2 also cause constitutive 
dauer formation and increased longevity. These phenotypes are suppressed by mutations that 
decrease the function of DAF-16, a forkhead transcription factor (35, 36). In our microarray 
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experiments, daf-16 mRNA was induced 1.7-1.9-fold by hypoxia in wild-type, hif-1 (ia04), 
or vhl-1 (oklôl) worms {p < 0.02 to p < 0.05) (supplemental data at 
http://www.jbc.org/cgi/content/full/M501894200/DCl). We performed RNA blot analyses to 
validate these findings, and these experiments showed that expression of daf-16 mRNA was 
-2-fold higher in worms treated with 0.5% oxygen for 4 h compared with normoxia-treated 
worms (Fig. 1C). Thus, increased daf-16 expression is a common feature of both hypoxia 
response and of perturbations in the DAF-2 signaling pathway which lead to constitutive 
dauer formation, increased longevity, and enhanced stress resistance (Fig. 6). 
The hif-1-dependent genes in Table I include the npc-1 NPCl homolog and the cam-1 
receptor tyrosine kinase. Both of these genes have been shown to regulate dauer formation 
negatively. The human NPCl gene is structurally related to the patched family of receptors, 
and it regulates intracellular cholesterol transport. Loss of human NPCl function is 
associated with Niemann-Pick type C disease. The C. elegans genome encodes two NPCl 
homologs, and deletion of either gene results in slow growth and hypersensitivity to 
cholesterol deprivation. Inactivation of both npc-1 and npc-2 causes a constitutive dauer 
phenotype (37, 38). Other studies have shown that mutants lacking the cam-1 kinase domain 
form dauers constitutively when they are cultured at 27 °C, a temperature slightly higher than 
the normal physiological range for C. elegans (39). This temperature-dependent phenotype 
was especially intriguing because hif-1 (ia04) mutants are unable to acclimate to high 
temperatures (40). Collectively, these data suggested that hif-1 -defective worms might 
exhibit a dauer constitutive phenotype at high temperatures. We tested this hypothesis and 
determined that hif-1 (ia04) mutants grew slower than wild-type worms at 27 °C, and 98% of 
the hif-1 mutants arrested as partial dauers (n = 236). Upon arrest, the hif-1 (ia04) partial 
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dauers were thin; they pumped their pharynxes slowly and sporadically; and they had thick 
cuticles. 
VHh-1 regulates HIF-1 function and other unknown pathway(s) 
Prior studies had demonstrated that C. elegans lacking vhl-1 function express HIF-1 
protein at constitutively high levels (6). Thus, we predicted that hypoxia-dependent changes 
in gene expression induced by HIF-1 would be abrogated in vhl-1-defective mutants but that 
inactivation of vhl-1 would have little effect on hif-1 -independent genes. Our data generally 
validate these models. For 60 of the 63 hif-1 -dependent genes, regulation by hypoxia was 
diminished in vhl-1 (oklôl) mutants, and 50 of the genes did not show a significant 
difference (p > 0.05) between mRNA levels in hypoxia and normoxia. In contrast, 39 of the 
47 genes in Table II exhibited significant regulation by hypoxia in vhl-1 mutants. 
Close examination of the raw data also provided evidence that VHL has hif-1-
independent functions. The gene R03A10.4 (predicted glutamine-phenylpyruvate 
transaminase) was not regulated by hypoxia, and mutation of hif-1 had little effect on its 
expression. However, animals lacking vhl-1 function expressed R03A10.4 at nearly 
undetectable levels (Fig. ID). Thus, VHL-1 appears to act through an HIF-1-independent 
mechanism to positively regulate the expression of R03A10.4. 
Discussion 
Cellular response to changing environmental levels of oxygen is critical for the 
survival of all metazoans. This study represents the first genomewide analysis of hypoxia 
response in C. elegans and demonstrates that hif-1 function is required for the majority of 
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mRNA expression changes in C. elegans hypoxia response. We have also presented 
compelling evidence for one or more HIF-1-independent pathways for implementing 
transcriptional responses to low oxygen. 
In humans response to hypoxia plays a central role in angiogenesis, tumor 
development, and cardiovascular disease. The hypoxia-inducible factor is thought to be the 
most important transcriptional regulator of mammalian hypoxic response during normal 
development and disease states (1, 14). Studies from other research groups have identified 
many genes regulated by HIF-1. Some of the genes that are transcriptionally activated by 
mammalian HIF-1 induce systemic responses to oxygen deprivation, such as increased red 
blood cell production and angiogenesis. Other HIF-1 targets modify the extracellular matrix, 
regulate glucose metabolism, or contribute to cellular survival in stressful conditions (41). 
Consistent with studies of mammalian HIF-1 function and with physiological studies 
of C. elegans oxygen utilization, we found that hypoxia induced the expression of many 
genes that regulate cellular metabolism. Adult C. elegans do not have a complex circulatory 
system and are ~1 mm in length. Any cell in the worm is only a few cell widths from the 
outer cuticle or the intestinal lumen (42), and oxygen delivery is likely accomplished by 
diffusion. Thus, we anticipated that the transcriptional targets of the C. elegans HIF-1 
complex would regulate cell-autonomous responses to oxygen deprivation. C. elegans can 
maintain near normal metabolic rates at environmental oxygen concentrations as low as 2% 
(25), and wild-type animals survive oxygen concentrations as low as 0.1% (26). In hypoxia 
(0.1-1% oxygen), C. elegans have been shown to decrease feeding, movement, and oxygen 
consumption (25). 
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The oxygen-requiring PHDs phy-2 and egl-9 are hif-1-dependentgenes 
The prolyl 4-hydroxylase enzymes that modify collagen in the endoplasmic reticulum 
require oxygen as a substrate. C. elegans has been shown to encode three prolyl 4-
hydroxylase a subunits. The expression pattern of phy-2 overlaps with that of two other a 
subunits, phy-1 and phy-3, in the hypodermis and in the spermatheca, respectively. The 
majority of the proteins in the worm cuticle are collagens, and double mutants lacking phy-1 
and phy-2 function are inviable (23, 33, 43). As shown in Fig. 1, C. elegans phy-2 mRNA 
was induced by hypoxia in an hif-1-dependent manner. Transcriptional regulation of the 
prolyl 4-hydroxylase a subunits by HIF appears to be evolutionary conserved (44). We 
have shown that p/zy-2-defective animals exhibit lethality and sterility in hypoxic conditions. 
These data fit a model in which phy-2 function, and perhaps increased transcription of phy-2, 
is required to offset decreased availability of oxygen substrate in hypoxic conditions. 
The EGL-9 PHD modifies HIF-1, thereby increasing its affinity for the VHL-1 E3 
ligase that targets HIF-1 for proteosomal degradation (6). Data in Table I and Fig. 1 show 
that egl-9 mRNA levels are regulated by C. elegans hif-1. This is in agreement with a recently 
published independent study (42). Positive regulation of egl-9 transcription by HIF-1 should 
help to maintain EGL-9 activity when oxygen substrate is limiting, and it may create a 
negative feedback loop to attenuate HIF-1 activation (Fig. 6). In humans, three PHD genes 
(EGL-9 homologs) have been identified, and PHD2 and PHD3 are induced by hypoxia (6,45, 
46). Thus, this regulatory mechanism is evolutionary conserved. 
In mammals, HIF-1 also induces the expression of CITED2, which competes with 
CBP/p300 for binding to HIF-1, thereby inhibiting transcriptional activation by HIF-1. HIF-1 
transcriptional repressors have not yet been identified in C. elegans. The C. elegans 
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homologs of HIF-1 and CBP have been shown to bind each other in yeast two-hybrid assays 
(47), but it is not yet known whether interaction of the native proteins is regulated by 
environmental oxygen concentrations. 
IIif-1-independentpathway (s) for hypoxia response 
Relatively little is known about the oxygen sensors and regulatory pathways that 
mediate transcriptional responses independent of HIF. The data presented in Table II and Fig. 
IB clearly demonstrate that there are hif-1-independent mechanisms for hypoxia adaptation in 
C. elegans. Consistent with these findings, others have shown recently that the transcription 
of certain hsplô small heat shock proteins is induced by hypoxia, and this induction does not 
require hif-1 function (48). 
For all 47 of the hif-1-independent genes, hypoxia causes significant differences in 
expression in the absence of hif-1 function, but in some cases, such as the F26A3.4 
phosphatase, the gene expression change is -2-fold less than that seen in wild-type animals 
(Fig. IB). This supports a model in which some genes are regulated by hypoxia via both hif-
1 -dependent and hif-1 -independent pathways. 
To compare hypoxia-induced changes in mRNA levels in different genetic 
backgrounds, we assayed animals from a defined developmental stage (L3) and at a single 
early time point. We expect that assays performed at other oxygen concentrations or other 
developmental stages will reveal additional hypoxia-responsive genes. Early HIF-1 targets 
likely control later responses to oxygen deprivation. 67 of the hypoxia-responsive genes in 
Tables I and II have known or predicted functions, and 26 of these are expected to mediate 
transcription or intracellular protein-protein interactions. For example, F26A3.4 (listed at the 
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top of Table II) encodes a protein-tyrosine phosphatase similar to the mammalian mitogen-
activated protein kinase phosphatase 6. Predicted transcription factors induced by hypoxia 
include the nuclear hormone receptors nhr-57 and nhr-88 and the T-box family members tbx-
33 and tbx-38. 
Oxygen levels and the dauer decision 
Dauers are resistant to several types of stress, including oxygen deprivation (34). 
Recent analyses have also shown that the putative HIF-1 binding site (HRE) is 
overrepresented in the putative regulatory sequences of genes up-regulated in dauers (49). 
This had led to the hypothesis that HIF-1 may act in concert with DAF-16 (the forkhead 
transcription factor that promotes longevity and dauer formation) to regulate some of the 
genes that confer resistance to hypoxic stress (49). As illustrated in Figs. 1 and 6, hypoxia 
increases both daf-16 expression and HIF-1 activity. Interestingly, some of the genes induced 
by HIF-1 inhibit dauer formation, and -defective animals form dauer-like larvae at high 
temperatures, even in the presence of abundant food. Because hif-1 mutants are unable to 
acclimate to higher temperatures (40), dauer formation may allow survival of stressful 
conditions that might otherwise be lethal to animals that are not expressing HIF-1 target 
genes at sufficient levels. 
Some responses to oxygen stress are post-translational. A recent study demonstrated 
that C. elegans will aerotax from 21% oxygen to 7% oxygen, and this response is mediated 
by gcy-35, which encodes an oxygen-sensing guanylate cyclase (50). C. elegans are 
standardly cultured in the laboratory in room air (21% oxygen). In the wild, C. elegans 
inhabits the soil, and the oxygen levels in soil containing ample supplies of its bacterial food 
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source could be substantially below 21%. In future studies, it will be interesting to investigate 
whether the expression of hypoxia-responsive genes varies significantly between 21% 
oxygen and the lower oxygen levels preferred by C. elegans. 
The microarray experiments reported here were not designed to compare gene 
expression patterns in vhl-1 mutant and wild-type animals directly, but we did find one gene 
that was regulated by VHL-1 but not HIF-1. An independent study has recently been 
published which identified additional C. elegans genes regulated by vhl-1 independently of 
hif-1 (42). This is especially interesting because mutations have been identified in the 
mammalian VHL tumor suppressor protein which predispose individuals to carcinomas, but 
do not impair HIF-1 a ubiquitination (51, 52). Further studies of HIF-1 a and VHL 
homologs in C. elegans may shed light on the shared and distinct cellular pathways that 
regulate tumori genesis. 
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TABLE I 
63 genes regulated by hypoxia in a hif-1-dependent manner 
Description Wild type H/N ratio" (p value) hif-1 (ia04> H/N ratio !p value) vhl-1 (ohiei) H/N ratio (p value) HRE 
fmo-12 Flavin-containing monooxygenase family member 6.31 (0.035) 0.78(0.3811 1.50 (0.53) 
W07A12.6 Predicted acyltransferase containing T on B-box 6.14 (0.005) 0.80 (0.537) 0.93 (0.74) 2 
F22B5.4 Unknown function 6.02(0.003) 1.21 (0.646) 1.24 (0.58) 4 
W07A12.7 Predicted acyltransferase 5.58 (0.005) 0.81 (0.531) 1.21(0.83) 3 
phy-2 Prolyl 4-hydroxylase usubunit/collagen synthesis 4.85 (0.005) 1.18 (0.641) 1.42(0.32) 3 
Y44A6C.1 Unknown function 4.59 (0.031) 1.83 (0.300) 1.97 (0.20) 1 
efk-l Homologous to eEF-2 kinase 4.21 (0.004) 1.74 (0.122) 1.98(0.69) 1 
nhr-57 Nuclear hormone receptor family member 4.09 (0.004) 1.80 (0.093) 1.72(0.10) 
F59B10.4 Unknown function 3.89 (0.007) 1.81 (0.100) 1.47(0.24) 1 
egl-9 DJ oxygen a se that negatively regulates hif-1 3.70 (0.003) 1.11 (0.796) 1.74(0.088) 1 
F45D11.16 Unknown function 3.42 (0.030) 0.98 (0.818) 1.62 (0.43) 
C24B9.9 Unknown function 3.24(0.016) 1.24 (0.658) 1.56 (0.27) 1 
dpf-6 Dipeptidyl peptidase IV family member 3.18 (0.009) 0.47 (0.029) 0.91 (0.52) 1 
W04E12.4 Unknown function 3.17(0.008) 1.72(0.114) 2.50 (0.025) 
C31G12.2 Contains domain found in C-type lectins 3.16 (0.015) 1.54(0.228) 2.46 (0.031) 
Y38E10A.23 Unknown function 3.12(0.038) 1.78 (0.159) 2.74 (0.03) 1 
R10D12.1 Sodium/phosphate transporter 3.11(0.038) 1.40 (0.446) 0.79 (0.46) 
K10H10.2 Cysteine synthase 3.07 (0.026) 0.92 (0.677) 1.18(0.61) 3 
npp-6 Predicted nuclear pore complex protein 3.05 (0.030) 1.62 (0.238) 1.96(0.17) 
C34D4.14 Predicted ubiquitin-protein ligase 3.04(0.016) 1.01 (0.969) 1.47 (0.24) 
Y15E3A.5 Unknown function 3.00 (0.016) 1.67 (0.181) 2.59 (0.022) 
inx-2 Innexin/putative gap junction protein 2.98 (0.019) 0.73(0.244) 1.10(0.83) 
K04H4.2 Predicted extracellular chitin-binding protein 2.98 (0.018) 0.63 (0.123) 0.58 (0.091) 
C04A2.1 Protein containing RabGAP/TBC domain 2.97(0.006) 1.10 (0.755) 1.06 (0.85) 1 
npc-I /ncr-1 Transmembrane protein orthologous to human NPCl 2.96 (0.002) 1.56 (0.084) 1.67 (0.050) 
T25E12.4 Serine/threonine protein kinase 2.92 (0.000) 1.23 (0.220) 2.00(0.004) 1 
M01H9.3 Unknown function 2.89 (0.016) 1.53(0.300) 1.94(0.095) 2 
F45D11.1 Protein containing DUF684 domain 2.87 (0.039) 0.90 (0.750) 2.07(0.10) 1 
CC8.2 Putative phosphatase regulatory subunit 2.8510.004) 1.37 (0.206) 1.93 (0.023) 
K02E7.6 Protein containing DUF684 domain 2.71 (0.025) 1.02 (0.944) 1.31 (0.48) 
fmo-14 Homologous to hepatic flavin-containing monooxygenase 5 2.66 (0.010) 1.18(0.679) 1.12(0.69) 1 
K08E3.1 Tyrosinase/ predicted oxidoreductase activity 2.64 (0.002) 1.26(0.326) 1.96(0.010) 4 
F45D11.2 Protein containing DUF684 domain 2.56(0.023) 0.94 (0.691) 1.73(0.11) 
F16G10.10 Protein containing DUF130 domain 2.46 (0.006) 1.28 (0.332) 2.22 (0.010) 
C56E6.2 Ras GTPase superfamily member 2.43 (0.021) 1.49 (0.265) 1.76(0.11) 1 
smg-2 Regulator of nonsense-mediated mRNA decay 2.38 (0.029) 1.11 (0.780) 1.15 (0.77) CCITV-Î Receptor tyrosine kinase orthologous to human ROR1, ROR2 2.37 (0.004) 0.82 (0.290) 0.86 (0.32) 
F57B9.1 Putative pyridoxamine-phosphate oxidase 2.36 (0.002) 1.10 (0.708) 0.97(0.70) 
F21D12.3 Putative transmembrane amino acid transporter protein 2.35 (0.00.3) 0.92 (0.474) 1.20(0.40) 2 
T08G3.6 Unknown function 2.34 (0.007) 1.51 (0.134) 1.85(0.034) 
pqn-43 Large protein containing prion-like (Q/N-rich! domains 2.32 (0.044) 1.14 (0.778) 1.50 (0.27) 3 
M02F4.1 Unknown function 2.32(0.019) 0.78 (0.291) 1.29 (0.54) 2 
Y46G5A.6 Protein containing F-box and helicase domains 2.28 (0.015) 1.50(0.125) 1.37 (0.21) 
zyg-9 Spindle pole component/regulates microtubule assembly 2.28 (0.016) 1.12 (0.643) 1.61(0.11) 1 
M05D6.5 Protein containing hypoxia-induced protein conserved region 2.28 (0.009) 1.06 (0.897) 1.46(0.16) 
C34B7.3 Cytochrome P450 2.28(0.001) 0.79 (0.134) 1.09(0.75) 1 
str-257 Member of the seven-transmembrane receptor gene class 2.25 (0.017) 1.31 (0.299) 1.88(0.043) 
T28F3.1 Protein containing copine and C2 domains 2.23 (0.038) 1.57(0.250) 2.56 (0.053) 1 
vab-1 Eph receptor tyrosine protein kinase 2.18 (0.004) 1.50 (0.052) 2.26(0.003) 
Y55F3BR.4 Predicted extracellular ligand-gated ion channel 2.17(0.016) 1.26 (0.439) 1.39(0.21) 1 
let- 75 Pharynx-specific type II myosin heavy chain (MHC D) 2.17(0.039) 0.65 (0.087) 0.76 (0.32) 
C40D2.4 Homeobox-containing protein 2.16 (0.022) 1.08 (0.939) 1.55(0.14) 
C29F9.5 Similarity to p300 transcriptional coactivator 2.15 (0.024) 1.42 (0.227) 2.25(0.022) 1 
C36A4.9 Putative acetyl-coenzyme A synthetase 2.15(0.021) 0.96 (0.790) 1.87 (0.063) 
K10H10.4 Unknown function 2.13(0.003) 1.25(0.221) 1.37(0.14) 
C32D5.12 Similarity to sterol dehydrogenases 2.11(0.017) 1.36 (0.332) 1.04 (0.85) 
Y19D10A.5 Transporter belonging to major facilitator superfamily 2.10 (0.004) 0.84 (0.244) 0.91(0.48) 
C01G6.9 Limited homology to human cetriolin 0.36 (0.008) 1.03 (0.748) 1.20(0.37) 
C41C4.1 Protein containing DUF595 domain 0.41(0.043) 0.68 (0.622) 1.06 (0.80) 1 
F35D11.10 Contains domain found in C-type lectins 0.43 (0.016) 0.83 (0.405) 0.93 (0.75) 
T07D1.3 Aldehyde dehydrogenase domain 0.47 (0.044) 1.23 (0.374) 2.56(0.010) 
Y9C9A.12 Protein containing F-box domain 0.46 (0.007) 0.78(0.222) 0.91 (0.92) 
F13H8.4 Unknown 0.48 (0.022) 0.71 (0.284) 0.84 (0.60) 
° H/N = mRNA expression in a hypoxic condition relative to mRNA levels in a normoxic condition. 
6 HRE = 5'-TACGTG, a motif similar to mammalian HRE, in the predicted 5'-regulatory region of the gene. 
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TABLE II 
47 genes regulated by hypoxia independently of hif-1 function 
Gene Description Wild type H/N ratio" 'p value! 
hif-1 (m04) h/n 
ratio ip value) vhl-1 (oklBl) H/N ratio (p value) 
F26A3.4 Protein containing dual specificity phosphatase domain 10.04(0.004) 4.71(0.029) 5.13(0.015) 
F26H11.3 Predicted transcription factor containing a bromodomain 8.76 (0.019) 4.69 (0.048) 6.41 (0.035) 
C12C8.1 Member of the Hsp70 family of heat shock proteins 5.60 (0.025) 11.73(0.009) 11.34(0.005) 
F08H9.4 Member of the Hspl6 family of heat shock proteins 5.28 (0.016) 6.79(0.004) 2.1 (0.14) 
F44E5.5 Member of the Hsp70 family of heat shock proteins 4.87 (0.027) 7.66(0.012) 17.3 (0.001) 
R166.5 Protein containing serine/threonine kinase domain 4.52(0.023) 3.54(0.042) 3.16(0.050) 
F44E5.4 Member of the Hsp70 family of heat shock proteins 4.49 (0.038) 6.45(0.021) 15.06 (0.001) 
F45D3.4 Unknown function 3.06(0.040) 4.18(0.030) 1.73 (0.021) 
W02D9.10 Unknown function 3.02(0.007) 3.80 (0.004) 2.71 (0.014) 
C07D10.2 Protein containing BTB/ POZ protein binding domain 2.99 (0.001) 1.74(0.022) 1.65(0.036) 
bli-3 NADPH oxidase required for dityrosine cross-linking of collagen 2.92 (0.0096) 1.77(0.048) 1.54(0.15) 
M04G7.3 Unknown function 2.91 (0.008) 1.97(0.036) 1.89 (0.037) 
gel-7 Predicted isocitrate lyase/malate synthase 2.82(0.015) 2.87(0.027) 2.54(0.026) 
tbx-33 T-box family transcription factor 2.77(0.002) 1.94(0.016) 2.39 (0.007) 
Y41D4B.22 Unknown function 2.72 (0.006) 2.06(0.025) 2.98 (0.005) 
Y22D7AR.1 Predicted protein-tyrosine phosphatase 2.60 (0.018) 2.00(0.042) 3.29(0.009) 
F58D5.8 Unknown function 2.55 (0.004) 2.14 (0.009) 2.40(0.006) 
ZK470.2 Unknown function 2.54(0.008) 1.93(0.027) 2.12(0.019) 
ptr-8 Member of the patched related family of transmembrane 2.51 (0.016) 2.76(0.012) 1.78(0.067) 
glycoproteins 
Y39G8B.2 Member of aldo/ketored uctase family 2.49 (0.006) 2.10(0.013) 2.55(0.007) 
Y75B8A.3 Predicted carboxylesterase 2.47 (0.024) 1.75(0.013) 3.70 (0.005) 
H23N18.3 Similar to UDP glucuronosyltransferases 2.40 (0.024) 2.04(0.036) 1.48 (0.22) 
Y75B8A.6 Predicted DNA-binding protein with two zinc finger domains 2.39(0.006) 2.24(0.010) 2.52 (0.007) 
sea-7 Sarco/endoplasmic reticulum Ca2+ ATPase homolog; ortholog of 2.32(0.031) 2.73(0.044) 1.60(0.17) 
human ATP2A1 
Y39G10AR.3 Protein containing ECC1 (regulator of chromosome condensation) 2.31 (0.017) 2.23 (0.024) 2.87(0.007) 
domain 
Homolog of period PAS domain protein 2.29(0.024) 2.34(0.033) 2.60 (0.017) 
F38B7.2 Unknown function 2.26 (0.021) 2.53(0.010) 1.51 (0.17) 
Y75B8A.19 Unknown function 2.26 (0.023) 2.50(0.021) 2.24(0.031) 
F47C12.2 Predicted extracellular protein containing lectin and CUB domains 2.25 (0.024) 1.88 (0.045) 2.86(0.012) 
pyc-1 Orthologous to the human gene pyruvate carboxylase 2.24 (0.038) 2.66(0.018) 2.40(0.018) 
K03B4.4 Unknown function 2.21(0.011) 1.79(0.049) 1.86(0.044) 
nhr-88 Member of the nuclear hormone receptor family 2.21 (0.019) 1.96(0.048) 2.76 (0.008) 
tmc-14 Protein that binds the UNC-51 protein kinase 2.21 (0.002) 1.78(0.009) 1.87 (0.006) 
F30B5.4 Unknown function 2.20 (0.004) 1.93(0.11) 2.30(0.004) 
K02F6.7 Unknown function 2.20(0.012) 1.83(0.045) 2.90 (0.004) 
mxl-3 Basic helix-loop-helix family of DNA-binding proteins; orthologous 2.18(0.018) 2.39(0.011) 2.74 (0.009) 
to human MAX 
E03H4.12 Predicted glucuronyltransferase 2.18 (0.004) 1.94(0.011) 2.16(0.005) 
tax-6 Ortholog of calcineurin A 2.16 (0.015) 1.92 (0.033) 1.7 (0.047) 
T16H12.5 Protein containing MATH and BTB/POZ protein binding domains 2.14(0.017) 1.86(0.047) 1.27(0.37) 
ZK849.1 Protein containing PDZ domain 2.12 (0.006) 1.61 (0.036) 1.71 (0.019) 
F40E12.2 Large intracellular protein with ankyrin and BRCT domains 2.11 (0.022) 1.76(0.041) 2.58 (0.009) 
F18A12.8 Encodes neprilsin; cleaves small signaling peptides 2.11 (0.000) 2.12(0.000) 2.40(0.0002) 
t.bx-38 T-box family transcription factor 2.07 (0.027) 2.41(0.018) 2.22(0.023) 
mod-o Sodium chloride-dependent serotonin transporter 2.05 (0.008) 1.61 (0.043) 2.03 (0.010) 
ins-22 Predicted type-it insulin-like molecule 0.28 (0.024) 0.42(0.132) 0.35 (0.045) 
T12B5.13 Protein containing FTH protein interaction domains 0.41 (0.023) 0.50(0.049) 0.63 (0.21) 
sru-22 Member of the class V serpentine receptor family 0.42 (0.002) 0.64(0.030) 0.57 (0.016) 
0 H/N = mRNA expression in a hypoxic condition relative to mRNA levels in a normoxic condition. 
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Figure Legends 
Figure 1. RNA blot analyses of genes regulated by hif-1 or vhl-1. mRNA was isolated 
from wild type (WT), hif-1 (ia04), vhl-1 (oklôl), or double mutant animals after incubation 
in 21% oxygen (N) or 0.5% oxygen (H) for 4 hours at 21°C. inf-1 serves as a loading control. 
Figure 2. Genomic distribution of hypoxia-responsive genes. Genes that are induced by 
hypoxia in wild-type, but not hif-1 (ia04) animals, are listed in red. Genes induced by 
hypoxia independent of hif-1 function are listed in blue. 
Figure 3. Viability assays in normoxia (21% oxygen) and hypoxia (0.5% oxygen). 
Animals carrying strong loss-of-function mutations in downstream targets of HIF-1 were 
incubated in 0.5% oxygen (hypoxia) or room air (normoxia) for 24 hours and then assayed 
for successful completion of embryogenesis (A) and survival to adulthood as previously 
described (103) (B). Numerical values are listed in Table S2 (supplemental data). Asterisks 
indicate that the viability of hypoxia-treated mutants is significantly lower than that of wild-
type (WT). 
Figure 4. Phy-2:GFP expression in an adult hermaphrodite. The positions of the vulva 
and the spermathecas are indicated with an asterisk and a's', respectively. 
Figure 5. Bacterial-mediated RNAi of 9 downstream targets of HIF-1. The percentage of 
C. elegans that completed embryogenesis and hatched is shown. Numerical values are listed 
in Table S3 (supplemental data). 
Figure 6. Models for hypoxia signaling and response. A. Proteasomal degradation of 
HIF-1 is mediated by EGL-9 and VHL-1 (68). B. Response to hypoxia is mediated by HIF-
1 and by HIF-1-independent pathway(s). The four largest functional categories of genes 
induced by each pathway are shown. HIF-1 positively regulates the expression of npc-1 and 
cam-1, which are negative regulators of dauer formation. This is consistent with constitutive 
dauer formation of hif-l(ia04) mutants at 27°C. daf-16 mRNA expression is induced by 
hypoxia independent of hif-1 function, and DAF-16 promotes dauer formation. 
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Supplemental Data Table S2. 
Hypoxia-dependent viability of animals carrying mutations in individual MfJ-dependent genes 
(data graphed in Figure 3) 
Strain Normoxia (21% 02) Hypoxia (0.5% 02) 
Hatched Grow to Nc Hatched Grow to adults Nc 
embryos (% )" adults (%)'"" embryos (%)a (%)*"" 
Wild type 96.6±2.1 98.9±1.6 586 97.6±2.3 97.0±3.2 522 
hif-1 (ia04) 98.5±1.2 100.0 510 58.2±23.2** 50.0±17.8*** 598 
^-2^77^ 94.9±3.9 100.0 414 22.3±4.8*** 9.7+5.0*** 473 
fmo-12(ok299) 98.9+0.8 96.3±1.1 508 88.8±2.5** 93.O+7.7 505 
fmo-14(ok294) 35.0+1.5 68.7±9.2 345 21.9±2.8** 74.5±7.9 424 
vab-l(e2) 91.3+2.4 85.4+7.5 520 86.3±6.0 72.2+4.2* 531 
cam-l(gml22) 79.8±6.0 48.2±6.8 520 78.8±4.2 59.0+14.6 424 
inx-2(ok3 76) 97.8±1.8 99.5±0.7 555 83.5±3.3** 85.9±7.4* 537 
egl-9(sa307) 100.0 100.0 262 97.1+3.4 100.0 276 
a Values are mean ± standard deviation 
b The values are calculated based on the number of hatched worms, 
c N is the total number of embryos from 3 independent treatments. 
* Different from wild-type value. Student r-test /7-value < 0.05. 
** Different from wild-type value. Student/-test p-value < 0.01. 
*** Different from wild-type value. Student t-test /rvalue <0.001. 
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Supplemental Data Table S3. 
Hypoxia-dependent viability upon RNAi depletion of individual /^/-dependent gem 
(data graphed in Figure 5) 
Normoxia (21% O?) Hypoxia (0.5% 02) 
Gene Hatched 
embryos (%)a 
Nb Hatched 
embryos (%)a 
Nh 
Vector 100.0 510 76.7±5.2 470 
99.6±0.7 497 34.0±12.4** 216 
W07A12.6 98.1±3.3 500 70.3+10.0 640 
F22B5.4 100.0 608 59.1+6.7* 364 
W07A12.7 100.0 392 72.1 ±9.5 321 
e/W 99.0±0.4 543 63.8±15.4 513 
nhr-5 7 99.5±0.4 570 65.8±2.6* 508 
K10H102 99.4 ±0.5 323 65.8±6.4* 409 
F57B9.1 100.0 435 70.9±6.7 362 
M05D6.5 99.5±0.5 509 61.2+10.5* 370 
C32D5.12 100.0 415 71.4+3.3 344 
a Values are mean ± SD (standard deviation). 
b N is the total number of embryos from 3 independent treatments. 
* Different from wild-type value. Student Mest p-value < 0.05. 
**Different from wild-type value. Student /-test/?-value < 0.01. 
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CHAPTER 3 
THE RHY-1 INTEGRAL MEMBRANE PROTEIN SUPPRESSES HIF-1 HYPOXIA-
INDUCIBLE FACTOR ACTIVITY IN CAENORHABDITIS ELEGANS IN A 
NEGATIVE FEEDBACK LOOP THAT DOES NOT INCLUDE VHL-1 
A manuscript to be submitted to Genetics 
Chuan S hen, Zhiyong Shao and Jo Anne Powell-Coffman 
Department of Genetics, Development, & Cell Biology 
Iowa State University, Ames, Iowa, 50011, USA 
Abstract 
The mammalian transcription factor hypoxia-inducible factor (HIF) controls many of 
the essential adaptive changes to varying oxygen levels during development, homeostasis, 
and tumorgenesis. The stability of the HIF a subunit is governed by the EGL-9 / EGLN 
family of proteins, which hydroxylate HIF a in an oxygen-dependent manner. Once 
hydroxylated, HIF a binds the von Hippel Lindau tumor suppressor (VHL) and is targeted 
for degradation. The nematode C. elegans has proven to be a powerful genetic model system 
for studying hypoxia signaling and response. The C. elegans orthologs of HIF a , EGLN, 
and VHL are the hif-1, egl-9, and vhl-1 genes, respectively. In this study, we describe two 
genes that function via ^-^-independent pathways to attenuate HIF-1 activity. First, we 
show that the EGL-9 prolyl hydroxylase inhibits HIF-1 transcriptional activity, in addition to 
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its well-described role in controlling HIF-1 stabilization. Second, we identify rhy-1, a gene 
encoding an integral membrane protein that is induced by HIF-1 and feeds back to inhibit 
HIF-1. Loss-of-function mutations in rhy-1 cause a modest increase in HIF-1 mRNA and 
protein expression, but rhy-1 mutants over-express some HIF-1 target genes at levels much 
higher than in vhl-1-defective mutants. Double mutants lacking vhl-1 and rhy-1 function 
have a more severe phenotype than either single mutant. We conclude that EGL-9 and RHY-
1 are essential components of negative feed back loops that attenuate HIF-1 function. 
Further study of these regulatory circuits may enable novel therapeutic approaches to 
mitigate hypoxia-characterized diseases such as human cancers. 
Introduction 
During development, homeostasis, and disease, aerobic organisms must constantly 
adapt to changing levels of environmental oxygen. In mammals, the hypoxia-inducible 
factor HIF-1, a DNA-binding transcription factor, regulates many of the critical 
transcriptional responses to hypoxia (1). HIF-1 target genes play central roles in cellular and 
systemic responses to hypoxia, including adaptive changes in angiogenesis/vascular 
remodeling, erythropoiesis, glucose/iron metabolism, cell proliferation/survival, and 
extracellular-matrix metabolism (1,2). Many common human diseases, including myocardial 
ischemia, stroke, peripheral vascular disease and chronic lung disease cause acute or chronic 
hypoxic stress (3). Therapies that increase HIF-1 activity may benefit patients afflicted with 
these and other cardiovascular illnesses. Alternatively, inhibitors of HIF-1 are being 
employed as cancer chemotherapeutic agents, as the survival and growth of solid tumors is 
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dependent upon adaptation to hypoxic microenvironments (4). It is, therefore, of central 
importance to elucidate the cellular and molecular networks that regulate hypoxia-inducible 
factor activity (5,6). 
HDF-1 is a heterodimeric transcription factor composed of a and (3 subunits. Both 
subunits contain basic helix-loop-helix (bHLH) and PER-ARNT-SIM (PAS) domains that 
mediate dimerization and DNA binding (7). The (3 subunit is also termed ARNT (aryl 
hydrocarbon receptor nuclear translocator). ARNT is broadly expressed, and it dimerizes 
with other bHLH-PAS proteins. The HIF a subunit is specialized for hypoxia response (8). 
There are three HIF a genes (HIF-la, HIF-2cc, and HIF-3oc) in mammals. HIF-2a and HIF-
3a exhibit tissue-specific expression patterns, and HIF-la is ubiquitously expressed. Mice 
lacking a functional HIF-la gene die early in embryogenesis with severe vascular defects 
(9,10). HIF-la contains two transactivation domains, which have been termed NT AD (N-
terminal) and CTAD (C-terminal). The CTAD has been shown to interact with a variety of 
transcriptional co-activators, including CBP/p300, SRC-1 and TIF-2 (11,12). 
The EGLN family (also called the PHD or HPH family) of prolyl hydroxylases are 
key regulators of oxygen-dependent HIF-1 protein stability (reviewed in (13-16)). In the 
presence of oxygen, specific proline residues (Pro-402 and Pro-564) in HIF-la are 
hydroxy!ated by members of the EGLN family (17-19). The EGLN enzymes are oxygen, 
iron, and 2-oxoglutarate dependent dioxygenases (20). Once hydroxylated, HIF-la binds to 
the von Hippel-Lindau (pVHL) tumor suppressor, the recognition component of an E3 
ubiquitin-protein ligase, and this results in ubiquitination and proteasomal degradation of 
HIF-la (21-23). Biochemical and physiological studies suggest that molecular oxygen 
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availability may limit EGLN activity in some tissues. HIF hydroxylases are therefore 
thought to act as oxygen sensors that regulate HIF-1 activity (17). Some EGLN genes are 
transcriptionally up-regulated by HIF-1. Since EGLNs help degrade HIF-1, they form 
negative feedback loops that limit HIF-1 activity (24). Recent studies have begun to 
elucidate the cellular signals and complex molecular networks that regulate EGLN enzymatic 
activity in vivo (reviewed in (14,16)). TCA cycle intermediates (25), reactive oxygen species 
(ROS) (26), and nitric oxide (27) have been shown to modulate EGLN activity and HIF-1 
protein levels. Intensive study of HIF-1 regulation has revealed several hypoxia-dependent 
and -independent strategies by which cells regulate HIF translation, protein stabilization, 
nuclear localization, DNA binding capacity, and transcriptional co-activator recruitment (28-
30). Recent studies also suggest that EGLN proteins may regulate HIF activity via other 
mechanisms, independent of their role in oxygen-dependent degradation of HIF alpha 
subunits (31,32). 
The nematode Caenorhabditis elegans has recently proven to be a powerful model 
system to study evolutionary conserved signaling pathways that regulate hypoxia response 
and the hypoxia-inducible factor (17,33). The C. elegans hif-1 and aha-1 genes are 
orthologous to mammalian HIFa and HIF (3 subunits, respectively (33,34). The hif-1 gene 
encodes the HIF-1 protein, and it controls most hypoxia-induced gene expression changes in 
C. elegans (35). /nj-i-deficient worms are less able to survive hypoxia (33,36). HIF-1 
protein stability is regulated by the evolutionary conserved EGL-9/VHL- 1/HIF-1 pathway 
(17). C. elegans egl-9 is orthologous to the mammalian EGLN genes, and the C. elegans 
homolog of the mammalian von Hippel-Lindau (pVHL) tumor suppressor is encoded by the 
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vhl-1 gene. C. elegans carrying loss-of-function mutations in vhl-1 or egl-9 express HIF-1 
protein at abnormally high levels in normoxic conditions (17). 
In this study, we investigate vhl-1-independent pathways that attenuate HIF-1 activity. 
We present evidence that EGL-9 regulates HIF-1 at two levels: first, it acts with VHL-1 to 
target HIF-1 for oxygen-dependent degradation; second, it functions independent of VHL-1 
to inhibit HIF-1 function. We also identify the rhy-1 gene, which acts in a negative feedback 
loop to inhibit expression of HIF-1 target genes. Loss-of-function mutations in rhy-1 cause a 
modest increase in HIF-1 mRNA and protein expression, but rhy-1 mutants over-express 
some HIF-1 target genes at levels much higher than in WzW-defective mutants. Double 
mutants lacking vhl-1 and rhy-1 function have a more severe phenotype than either single 
mutant. Collectively, these data support a model in which RHY-1 and EGL-9 function in 
VHL-1-independent pathway(s) to regulate HIF-1 localization or transcriptional activity. 
Experimental Procedures 
Strains and genetics 
Wild-type worms were C. elegans Bristol strain N2. Worms were grown at 20°C 
using standard methods (37). The following strains were used in this work: 
ZG313 [rhy-1 (okl402)]\ ZG369 [rhy-1 (okl398)\, ZG31 [hif-1 (ia04)}\ JT307 [egl-9(sa307)]; 
MT1216 [egl-9(n586)\, MT1201 [egl-9(n571)]; CB5602 [vhl-l(okl61)]• ZG317 [rhy-
l(okl402) hif-1 (ia04)]\ ZG315 [rhy-l(okl402) egl-9(sa307)]\ ZG318 [rhy-1 (okl402) vhl-1 
(okl61)\\ ZG316 [hif-1 (ia04) egl-9(sa307)]; ZG229 [vhl-l(okl61) unc-119 (ed3)]; ZG321 
[vhl-l(oklôl) egl-9(sa307)]\ ZG301 [rhy-1 :gfp(iaEx51)]; ZG350 [rhy-1 :gfp(iaEx69)]; 
ZG311 [vhl-l(okl61) rhy-1 :gfp(iaEx57)]\ CB4856 Hawaii SNP mapping strain; DR 103 [dpy-
10(el28) unc-4(el20)]; SP636 [unc-4(el20) mnDf67/mnCl dpy-10(el28) unc-52(e444)] 
Genomic integration of the nhr-57:GFP reporter 
The nhr-57:GFP construct was a gift from Dr. Piali Sengupta (38). The nhr-57:GFP 
construct was integrated into the worm genome using microparticle bombardment (39). C. 
elegans ZG229 [vhl-1 (oklôl) unc-119 (ed3)] hermaphrodites at the LA to young adult stage 
were used for microparticle bombardment. The bombardment was carried out using a 
BioRad Biolistic PDS/HE 1000 device, 28 inches of Hg vacuum, and 650 p.s.i. rupture disc 
pressure. For each bombardment, 1 /xg of unc-119 rescue plasmid pDP#MM016b (a gift 
from Dr. Judith Austin) and 0.5 ng nhr-57:gfp plasmid (a gift from Dr. Piali Sengupta) were 
coupled to 0.1 mg of 0.6-jum microcarrier gold beads, and the beads were bombarded onto a 
layer of ZG229 hermaphrodites within a 35-mm diameter circle on 100-mm NGM plates 
without OP50. Worms were recovered onto "opti-gro" plates with OP50 lhr after 
bombardment. Non-zmc rescued transformants were identified two weeks after the 
bombardment. The ials07 insertion was mapped to LGIV using single-nucleotide 
polymorphisms (40). The reporter then was crossed into various mutant backgrounds. The 
worm strains used in the paper include: ZG120 [Bristol strain N2 nhr-57:gfp(ials07)\; ZG304 
[rhy-l(okl402) nhr-57:gfp(ials07)]; ZG370 [rhy-l(okl398) nhr-57:gfp(ials07)]; ZG302 [egl-
9(sa307) nhr-57:gfp(ials07)]\ ZG323 [egl-9(n571) nhr-57:gfp(ials07)]; ZG324 [egl-9(n586) 
nhr-57:gfp(ials07)]\ ZG119 [vhl-l(oklôl) nhr-57:gfp(ials07)\, ZG357 [rhy-1 (ia38) unc-
4(el20) nhr-57:gfp(ials07)]; ZG331 [rhy-l(okl402) hif-l(ia04) nhr-57 : gfp(ials07)]\ ZG346 
[rhy-1 (okl402) egl-9(sa307) nhr-57:gfp(ials07)\, ZG312 [rhy-l(okl402) vhl-l(okl61 ) nhr-
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57:gfp(ials07)]; ZG347 [hif-l(ia04) egl-9(sa307) nhr-57:gfp(ials07)]\ ZG174 [hif-l(ia04) 
vhl-l(oklôl) nhr-57:gfp(ials07j\; ZG325 [egl-9(sa307) vhl-l(oklôl) nhr-57:gfp(ials07)]; 
ZG194 [CB4856 vhl-l(oklôl) nhr-57:gfp(ials07j\ 
Genetic screen and mapping of ia38 
The worm strain ZG119 described above was used for EMS mutagenesis according 
the standard F2 mutant screening method (41). The ia38 mutation was mapped by a 
combination of single-nucleotide polymorphisms (40), deletion mapping, and three-point 
mapping (http://www.wormbook.org). To create a strain suitable for mapping mutations 
relative to single-nucleotide polymorphisms (SNPs), the Hawaii strain CB4856 was crossed 
ZG119 [vhl-1 (oklôl) nhr-57:gfp(ials07)] to generate the strain ZG160. ZG160 was then 
backcrossed to CB4856 three times to create the strain ZG194 [CB4856 vhl-l(oklôl) nhr-
57 :gfp(ials07)]. ZG194 is homozygous for at least 15 SNPs from the Hawaiian strain, and 
these were used to map mutations to specific chromosomes. Linkage of mutations to SNPs 
was assayed by bulk segregated analysis (40). Three point mapping placed the ia.38 mutation 
between dpy-10 and unc-4 on LGII, at the approximate genetic map position 1.07 cM. 
Sequencing of rhy-1 alleles 
Genomic DNA was isolated from N2, rhy-1 (ia38), rhy-1 (okl402), and rhy-1 
(okl398) worms. Fragments of rhy-1 genomic DNA were PCR-amplified using the forward 
primer 5 ' -CTCCCCGTTAC ATTTTGC AT and the reverse primer 5'-
TGGGTGGCAAAAGAAAACAT. The wild-type band and deletion band were gel 
extracted and purified using the Perfectprep Gel Cleanup kit (Eppendrof), and sequenced. 
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Generation of rhy-1 expression constructs 
To generate the rhy-1 :GFP construct pSC09, DNA was PGR amplified using the 
forward primer (PstI) 5 ' -GGCGCTGC AGCTTGGT A AGCTG ACTTTC A AC ACG and the 
reverse primer (BamHI) 5 ' -GCGGGATCCCGTGTGGCATATTGAGATGTCAAATG. The 
PCR product included the rhy-1 1.8kb upstream promoter sequence and whole genomic 
sequence except the sequence for the last four codons. To construct pSC15, DNA was PCR 
amplified using the forward primer (PstI) 5 ' -CACCTGCAGCAATGTATTTCAAAGAAGG 
and the reverse primer (Xbal) 5'-GTGTCTAGATGGCGATGATGACATATATGTC. The 
PCR product included 1.8kb upstream promoter sequence and +15bp relative to the rhy-1 
translational start site. The PCR products were cloned into the GFP vectors pPD95.75 and 
pPD95.77, respectively (provided by A. Fire, Carnegie Institution of Washington). To create 
transgenic animals, the DNA was coinjected with the pRF-4 rol-6 marker (42). Three 
independent transgenic lines were examined for each construct. 
Western blots 
L4-stage worms were collected and boiled for 5min in IX SDS sample buffer 
prepared as described (43). The samples were loaded to a 10% SDS-PAGE gel, size 
fractionated, and transferred onto Pure Nitrocellulose membrane (Osmonics Inc.). To detect 
nhr-57\GFP, 20 L4-stage worms were used in each sample. A commercially available GFP-
specific mAb (Roche Diagnostics) was used in 1:1,000 dilution. Secondary antibody (anti-
mouse IgG+IgM from rabbit, Pierce) was used in 1:2,000 dilution. To detect HIF-1 protein, 
80 micrograms of L4-stage worm extract was used. Polyclonal anti-HIF-1 was a gift from Dr. 
Peter J. Ratcliffe. This antibody was produced by rabbits immunized with a glutathione-S-
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transferase fusion protein that included amino acids 360-498 of C. elegans HIF-1 (17). This 
anti-HIF-1 was used in 1:1,000 dilution, and secondary antibody (anti-rabbit IgG from goat, 
Jackson, ImmunoResearch) was used in 1:2,000 dilution. The Western blot images were 
analyzed by Image J software. 
Real-time RT-PCR 
Synchronized L4-stage worms were grown on 100mm plates, using standard methods. 
Total RNA was isolated using Trizol reagent. RNA samples were treated by TURBO DNA-
free kit (Ambion) to remove the DNA contamination. 1/ig total RNA from each sample was 
converted to complementary DNA using the Anchored Oligo(dT) primer according to the 
manufacturer's protocol (EndoFree RT kit, Ambion). 50ng total RNA from each sample was 
used for each real-time RT-PCR reaction using the Full Velocity SYBR Green QPCR Master 
Mix Kit (Stratagene). Quantitative RT-PCR was performed using the Stratagene Mx4000 
multiplex PCR system. The specific primers for K10H10.2, F22B5.4, and inf-1 were 
designed and synthesized by Integrated DNA Technologies. The standard curve method was 
used to analyze the expression levels, inf-1 is not regulated by hypoxia (35) and was used as 
a control. The experiments were repeated in triplicate. 
Results 
To develop a visual assay for HIF-1 transcriptional activity, we examined the 
expression of reporter constructs in which the expression of green fluorescent protein (GFP) 
was controlled by regulatory sequences from HIF-1 target genes (35). Of the reporters that 
we assayed, nhr-57:GFP (38) was the most reliable reporter of HIF-1 function. We 
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integrated the nhr-57:GFP reporter into the genome, using microparticle bombardment. The 
expression pattern is shown in Figure 1. Consistent with previous studies, we found that nhr-
57 :G¥P was expressed at very low levels in wild-type animals in room air (Fig 1A; (38)). 
Hypoxia treatment increases nhr-57:GFP levels markedly (Fig 1C). Mutants defective for 
vhl-1 express HIF-1 protein and nhr-57 mRNA at constitutively high levels [Fig 2A; 
(17,35,44)]. As shown in Fig IE, the n/zr-57:GFP reporter was expressed at high levels in 
vhl-1 mutants, and nhr-57:GFP expression requires hif-1 (Fig 1G). Thus, nhr-57:GFP is a 
useful reporter of HIF-1 activity. 
Vhl-1 -independent functions of egl-9 
We were intrigued to find that eg/-9-deficient animals expressed nhr-57:GFP at 
higher levels than did vhl-1 mutants, as assayed by fluorescence and by immunoblots (Fig 1Q 
lanes 3, 6-8). While expression of the reporter was strongly enriched in the intestine of vhl-1 
(oklôl) animals (Fig IE), nhr-57:GFP fluorescence was also visible in the hypodermis and 
pharynx of egl-9 mutants (Fig II). To further characterize the egl-9 mutant phenotype, we 
employed RT-PCR to quantitate expression K10H10.2 and F22B5.4 mRNAs. Prior studies 
had shown that these two genes were induced by hypoxia in a /zz/-i-dependent manner (35). 
As shown in Figure 2, vhl-1-deficient worms expressed K10H10.2 mRNA at levels 2.8 times 
higher than found in wild type. By comparison, the levels of K10H10.2 mRNA in egl-9 
mutant worms was 30.5 times greater than in wild type animals. This difference between the 
egl-9 and vhl-1 mutant phenotypes was highly significant (Fig 2B, p < 0.00001). Analysis of 
F22B5.4 mRNA levels revealed a similar pattern. Mutation of vhl-1 or egl-9 caused 
increases in F22B5.4 mRNA of 10.7-fold and 42.3-fold, respectively (Fig 2B). In an 
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independent study, Bishop et al (44) reported that several HIF-1 target genes were expressed 
at higher levels in egl-9 mutants compared to vhl-1 mutants. Collectively, these studies 
provide strong genetic evidence that EGL-9 acts through both VHL-1-dependent and VHL-1 -
independent pathways to inhibit HIF-1 function. 
We considered the possible mechanisms by which EGL-9 might decrease expression 
of HIF-1 target genes independent of VHL-1. One possibility was that once HIF-1 was 
hydroxylated by EGL-9, it was targeted for degradation by an E3 ligase other than VHL-1. 
This model predicted that HIF-1 protein levels would be significantly higher in egl-9 mutant 
animals, compared to vhl-1 mutant animals. We employed immunoblots to test this 
hypothesis (Fig 2A). HIF-1 protein was expressed at similar levels in vhl-1 (oklôl) and egl-
9 (sa307) animals (4.5-fold to 4.8-fold greater than wild-type). We also examined the 
expression of a transgene in which HIF-1 protein was tagged with GFP (33). Strong loss-of-
function mutations in vhl-1 or egl-9 resulted in similar levels of HIF-1:GFP expression (data 
not shown). Thus, EGL-9 and VHL-1 act in concert to regulate HIF-1 protein levels, and 
EGL-9 has a separate VHL-1-independent function by which it inhibits HIF-1 function. 
Rhy-1, an integral membrane protein that inhibits HIF-1 function 
To further define the vhl-1-independent pathway(s) by which egl-9 regulated HIF-1, 
we employed two experimental strategies. First, we initiated a forward genetic screen to 
identify mutations that caused an nhr-57:GFP expression pattern similar to that seen in egl-9 
mutants (described below). Second, we used RNAi to test the hypothesis that some HIF-1 
target genes might be negative regulators of HIF-1 function. C. elegans EGL-9 and the 
mammalian EGLN1/PHD2 and EGLN3/PHD3 genes were known to function in negative 
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feedback loops to attenuate HIF activity (24,35,44,45). Similarly, the mammalian CITED2 
gene has been shown to be induced by HIF-1, and it feeds back to block binding of HIF-
1 alpha to CBP/p300 (46). To test the hypothesis that some genes activated by C. elegans 
HIF-1 functioned to limit HIF-1 activity, we used bacterially-mediated RNAi (47) to reduce 
expression of nine genes that had been shown to be induced by HIF-1 (35). RNAi for 
W07A12.7 increased and expanded nhr-57:GFP expression. This phenotype was similar to 
that exhibited by egl-9 mutant worms (data not shown, rhy-1 mutant phenotype described 
below). Based on the characterization of the mutant phenotype described below, the 
W07A12.7 gene has been named rhy-1 (regulator of /rypoxia-inducible factor). 
Concurrently, we isolated the ia38 allele in a screen for chemically-induced mutations 
that caused over-expression the nhr-57:GFP reporter. Animals that were homozygous for the 
ia38 mutation exhibited a phenotype similar to that caused by rhy-1 RNAi. We mapped ia38 
to a 1.1 cM genomic interval between dpy-10 and unc-4 on chromosome II. The mutant 
phenotype and genomic location suggested that the ia38 mutation might be in the rhy-1 gene. 
In support of this hypothesis, we determined that an extrachromosomal array containing a 
wild type copy of rhy-1 was able to rescue the ia38 phenotype. We sequenced rhy-1 in ia38 
mutants and determined that ia38 is a missense mutation that changes a conserved serine to 
phenylalanine (the position of Serl57 is indicated by an arrow in Fig 3A & 3B). The C. 
elegans Knockout Consortium isolated two deletion mutations in rhy-1. The okl402 and 
okl398 deletions are diagrammed in Fig 3A. The okl402 lesion deletes the region that 
encodes amino acids 246 - 429 (over 36% of the predicted rhy-1 coding sequence), and we 
used this allele for the phenotypic analyses described below. okl398 deletes the sequence 
encoding amino acids 86 - 337. Animals that are homozygous for either okl398 or okl402 
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over-express the nhr-57: GFP reporter, and this phenotype is suppressed by a strong loss-of-
function mutation in hif-1 (Fig 1M, lO, and data not shown). The deletion mutations fail to 
complement the ia38 allele. We conclude that rhy-1 acts in a negative feedback loop to 
inhibit HIF-1 function. 
rhy-1 belongs to the acyltransferase-3 gene family. The acyltransferase-3 domain is 
found in a range of bacterial acyltransferase enzymes, but the molecular function(s) of these 
genes in metazoans is unknown. The serine residue that is mutated in the rhy-1 (ia38) allele 
is highly conserved. An alignment of this region, including worm, human, mouse and 
bacterial proteins, is shown in Fig 3B. RHY-1 is predicted to be an integral membrane 
protein with 11 transmembrane domains. We note that a neighboring gene, W07A12.6, is 
predicted to encode a protein 78% identical to the rhy-1 gene product. As found with rhy-1, 
W07A12.6 mRNA is induced by hypoxia in a HIF-1-dependent manner (35). C. elegans nrf-
6 and ndg-4 are also members of the acyltransferase-3 gene family. Loss-of-function 
mutations in ndg-4 or ntf-6 cause defects in yolk lipoprotein export from intestinal cells and 
confer resistance to fluoxetine (Prozac) (48,49). nrf-6 loss-of-function mutants do not mis-
express the nhr-57:GFP reporter. 
Comparison of rhy-1 and egl-9 loss-of-function phenotypes 
The morphological defects in rhy-1 (okl402) and egl-9 (sa307) mutants are similar, 
and the two mutations result in comparable patterns of nhr-57:GFP expression (Fig II & 1M). 
The egl-9 egg laying defect is suppressed by a strong loss-of-function mutation in hif-1 (44). 
Thus, the morphological defects in eg/-9-deficient worms are due, in large part, to 
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abnormally high levels of HIF-1 function, rhy-1 mutants also exhibit egg-laying defects and 
are slightly dumpy, and the hif-1 (ia04) mutation suppresses these morphological defects. 
Interestingly, these analyses also revealed some differences in the rhy-1 and egl-9 
mutant phenotypes. The rhy-1 (okl402) hif-1 (ia04) double mutants produced an average of 
only 21 self-progeny per hermaphrodite (45 broods scored). By comparison, the rhy-1 
(okl402) mutation reduced the brood size much less dramatically, to 188 self-progeny. 
Wild-type hermaphrodites and hif-1 (ia04) single mutants produced 251 and 253 self-
progeny, respectively (20 broods assayed). The low fecundity of rhy-1, hif-1 double mutant 
hermaphrodites could be rescued by mating to wild-type males. This indicates that rhy-1 
(okl402), hif-1 (ia04) double mutant hermaphrodites produce low numbers of functional 
sperm. In contrast, egl-9 (sa307) hif-1 (ia04) double mutants have normal brood sizes. 
These analyses suggest that rhy-1 and egl-9 both act to inhibit expression of certain HIF-1 
target genes, but rhy-1 has roles in sperm development that do not require egl-9 function. 
RHY-1 expression pattern 
The rhy-1 -defective phenotypes suggest that rhy-1 function is required in multiple 
tissues. To gain further insight to RHY-1 function, we created two RHY-1 :GFP reporter 
constructs and assayed their expression patterns. The pSC09 fusion gene includes all 
predicted rhy-1 coding sequences, the three rhy-1 introns, and 1.7 kb of sequence 5' to the 
start codon (Figure 4A). This fusion gene can rescue the phenotype of three rhy-1 alleles, as 
assayed by nhr-57:GFP expression, but pSC09 is expressed at very low levels. Therefore, 
we created a second reporter, pSC15, that did not include most rhy-1 coding sequences (Fig 
4A). The pSC15 reporter was highly expressed in the intestine and head sensory neurons 
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(Fig AC). The reporter was also expressed at lower levels in body wall muscle, socket cells 
and vulval muscles. A prior study had shown that egl-9:GFP was expressed in pharyngeal 
muscle, body wall muscle, vulval muscles and sensory neurons of the head and tail (50). 
Thus, the expression patterns of RHY-1 :GFP and EGL-9:GFP partially overlap. 
Unfortunately, the low expression level of pSC09 RHY-1:GFP precluded higher 
resolution analyses of the expression pattern. In order to visualize the cellular and 
subcellular expression pattern of RHY-1: GFP, we crossed the pSC09 reporter into vhl-1-
defective animals (which overexpress rhy-1 and other genes that are positively regulated by 
HIF-1). Intestinal expression of RHY-1 :GFP visibly increased in vhl-l(oklôl) mutants, but 
hypodermal expression did not. It is interesting to note that mutation of vhl-1 also increased 
intestinal, but not hypodermal expression of nhr-57:GFP (Fig IE). RHY-1 :GFP expression 
was predominantly peri-nuclear (Fig 4B), and it was also faintly visible on cell surfaces. 
These observations are consistent with in silico analyses (http://psort.nibb.ac.jp) that predict 
RHY-1 is localized to the plasma membrane or the endoplasmic reticulum. 
RHY-1 inhibits HIF-1 activity via a VHL-1-independentpathway 
To confirm that rhy-1 inhibited the expression of HIF-1 target genes other than nhr-
57:GFP, we assayed two endogenous mRNAs, K10H10.2 and F22B5.4, by real-time RT-
PCR. Mutation of rhy-1 significantly increased the expression of both genes (p < 0.0001 and 
p < 0.01, respectively; Fig 5A, 5B). As expected, inactivation of HIF-1 diminished the 
overexpression of HIF-1 targets in a rhy-1 mutant background (Fig 5A & 5B). Expression of 
K10H10.2 and F22B5.4 mRNAs was higher in rhy-1 (okl402) vhl-1 (oklôl) double mutants 
than in either single mutant. This was consistent with the observation that the double 
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mutants also expressed the nhr-57:GFP reporter at higher levels than either single mutant 
(Fig5C). 
To address whether RHY-1 regulated HIF-1 expression, HIF-1 activity, or both, we 
assayed hif-1 mRNA and HIF-1 protein levels. The rhy-1 (okl402) mutation resulted in a 
slight increase in hif-1 mRNA levels (1.8 fold) (Fig 5D) and HIF-1 protein (2.2 fold) (Fig 5E). 
By comparison, HIF-1 protein levels in vhl-1 (oklôl) and egl-9 (sa309) animals were 4.8-
fold and 4.5-fold greater than in wild type animals (Fig 5E), while hif-1 mRNA levels were 
not changed (Fig 5D). Thus, comparison of the vhl-1 and rhy-1 mutant phenotypes indicates 
that HIF-1 protein levels were higher in vhl-1 -deficient animals; however, expression of HIF-
1 target genes was higher in rhy-1 mutants. This is consistent with a model in which RHY-1 
has a minor effect on HIF-1 protein expression and functions primarily in a VHL-1-
independent pathway to limit HIF-1 function. 
If EGL-9 and RHY-1 acted in distinct pathways, then we would expect that the 
expression of HIF-1 target genes might be higher in the double mutant than in either single 
mutant. We quantitated the expression of nhr-57:GFP protein, K10H102 mRNA, and 
F22B5.4 mRNA in rhy-1 (okl402), egl-9 (sa307) and double mutant animals. For all three 
genes assayed, expression in rhy-1, egl-9 double mutants was not enhanced relative to 
expression in egl-9 single mutants (Fig 6A & B). While not conclusive, these data leave 
open the possibility that RHY-1 and EGL-9 function in the same pathway. 
Discussion 
The transcription factor HIF is a central regulator of physiological and pathological 
adaptation to hypoxia. The regulation of HIF activity occurs at the multiple levels, and the 
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cellular networks that control HIF include negative and positive interactions (reviewed in 30, 
(51,52). Here we employ genetic strategies to further understand the regulatory circuits that 
control transcriptional responses to hypoxia. 
Dual functions for EGL-9 
In this report we provide evidence that EGL-9 inhibits HIF-1 function via VHL-1 -
independent pathway(s), in addition to its well-described role in controlling HIF-1 
stabilization. EGL-9 and certain other members of the 20G-Fe (II) dioxygenase superfamily 
have been shown to play essential roles in the regulation of HIF (17). In C. elegans, EGL-9 
hydroxylates HIF-1 in an oxygen-dependent manner. This modification results in VHL-1 
binding and subsequent ubiquitination and proteasomal degradation of HIF-1. We observed 
tremendously enhanced expression of nhr-57::GFP in egl-9 mutant worms, compared with 
vhl-1 mutant worms. Further, we confirmed that mRNA levels of two additional HIF-1 
target genes were expressed at significantly higher levels in ggZ-9-deficient worms relative to 
vM-i-deficient worms. Similar observations were reported in an independent study (44). 
Importantly, we determined that vM-i-deficient worms and <?g/-9-deficient worms expressed 
HIF-1 protein at similar levels. These results provide strong support for a model in which 
EGL-9 inhibits expression of HIF-1 target genes by an uncharacterized mechanism which is 
independent of VHL-1. It is not yet clear whether the VHL-1-independent functions of EGL-
9 require 20G-Fe (II) dioxygenase activity. Bishop et al. (44) showed that similar levels of 
nhr-57 mRNA were detected in animals treated with Fe (II) chelating compounds and in vhl-
1 mutants. This was the expected result, as pharmacological inhibition of the EGL-9 enzyme 
should block VHL-1-mediated degradation of HIF-1. However, egZ-9-deficient worms 
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expressed nhr-57 mRNA at much higher levels. This observation suggests that the VHL-1-
independent pathway(s) by which EGL-9 inhibits HIF-1 may not require 20G-Fe (II) 
dioxygenase activity. 
Two recent studies in mammalian cell lines provide further insight to mechanisms by 
which EGLN proteins might regulate HIF activity independent of VHL. Ozer et al. (31) 
showed that EGLN l/HPH-2 can form a complex with the candidate tumor suppressor ING4. 
Additionally, EGLN l/HPH-2 and ING4 were shown to associate with DNA binding sites for 
HIF. This study supports a model in which HPH-2/EGLN1 recruits ING4 and transcriptional 
repressors to the HIF complex, thereby inhibiting the expression of HIF target genes. To and 
Huang (32) also presented evidence that EGLN1 inhibits HIF-la transcriptional activity, 
independent of the VHL pathway that regulates HIF-la protein stability. When considered 
with these studies, the C. elegans data are consistent with the following model: EGL-9 binds 
HIF-1 at the conserved LXXLAP motif in the ODD domain. When the oxygen concentration 
is sufficiently high, EGL-9 hydroxylates HIF-1, resulting in binding to VHL-1 and 
subsequent degradation of HIF-1 (17). In hypoxic conditions, the EGL-9/HIF-1 complex 
translocates into the nucleus, and EGL-9 recruits certain transcriptional repressors to the 
regulatory regions of HIF-1 target genes. It is interesting to notes that the EGL-9 protein 
includes an N-terminal MYND-type zinc finger domain, and this protein motif is present in 
certain transcriptional repressors (53-55). Future studies will test hypotheses predicted by 
this model. 
RHY-1 
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Under hypoxic conditions rhy-1 expression is induced by HIF-1, and RHY-1 feeds 
back to attenuate HIF-1 activity. In this report, we demonstrate that RHY-1 inhibits 
expression of HIF-1 target genes via a mechanism is distinct from the VHL-1-mediated 
pathway that controls HIF-1 protein levels. The supporting lines of evidence are as follows: 
1) The HIF-1-dependent nhr-57::GFP reporter is expressed in distinct patterns and at 
significantly different levels in r/ry-./-deficient worms and vhl-1 -deficient worms; 2) hif-1 
mRNA levels and HIF-1 protein levels are only moderately increased (-2-fold) in rhy-1 loss-
of-function mutants. Deletion of the vhl-1 gene causes much higher HIF-1 protein levels 
(-5-fold). However, HIF-1 transcriptional activity, as assayed by nhr-57:GFP and K10H10.2 
mRNA level, is significantly higher in rhy-1 mutants than in vhl-1 mutants. This indicates 
that RHY-1 regulates HIF-1 transcriptional function, but not HIF-1 protein stabilization; 3) C. 
elegans that carry loss-of-function mutations in both rhy-1 and vhl-1 express significantly 
higher levels of HIF-1 target genes compared with each single loss-of-function mutant. 
rhy-1 encodes a predicted multipass transmembrane protein belonging to the 
acyltransferase-3 family, which contains a large number of proteins with uncharacterized 
function in C. elegans. To further understand the function of rhy-1, we examined other 
similar acyltransferase-3 proteins in worms. W07A12.6 is a neighboring gene of 
W07A12.7/z7ry-7, and W07A12.6 encodes a protein having high similarity to RHY-1. 
W07A12.6 mRNA was also induced by hypoxia in a HIF-1-dependent manner (35). 
Although rhy-1 is expressed at high level, W07A12.6 is expressed at very low level in worms 
(http://www.wormbase.org). We did observe that the HIF-1-dependent nhr-57::GFP reporter 
was over-expressed in W07A12.6 RNAi (Data not shown). However, the phenotype could 
be caused by that rhy-1 shares substantial sequence identity with this gene and is as a 
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secondary target of W07A12.6 RNAi. To investigate if W07A12.6 could rescue the 
phenotype of rhy-1 mutants, we generated a construct in which the rhy-1 promoter was fused 
with the W07A12.6 coding region. However, the transgenic worms carrying the construct 
were too sick to survive. Apparently, mis-expression of W0712.6 is toxic to worms. The C. 
elegans gene nrf-6 also encodes an acyltransferase-3 family protein with similarity with 
RHY-1. nrf-6 was shown to be required for antidepressant fluoxetine-induced nose 
contraction and intercellular yolk transportation in C. elegans (49). It is unlikely that RHY-1 
and NRF-6 function at the same pathway, because our HIF-1-dependent reporter was not 
over-expressed in nrf-6 loss-of-function mutants. However, it is intriguing to note 
similarities in these two proteins, including predicted 11 transmembrane topology and 
expression in the intestine and hypodermis. 
A large number of acyltransferase-3 family proteins are existed in Bacteria, and these 
genes function mainly as O-acyltransferases, O-antigen acetylases, and lipo-oligosaccharide 
acyltransferases. The biological functions that have been described include biosynthesis of 
lipopolysaccharide and glue an pathogenesis factors (56-60) and biosynthesis of antitumor 
and antibiotic agents such as maytansinoid and macrolide (61-63). A recently published 
study showed that gene nrf-5, which functions in the same pathway as nrf-6 for fluoxetine 
sensitivity and yolk transport, encodes a protein homologous to a family of secreted lipid-
binding proteins that includes mammalian bactericidal/permeability-increasing protein (BPI), 
lipopolysaccharide-binding protein (LBP), cholesteryl ester transport protein (CETP), and 
phospholipids lipid transport protein (PLTP) (48). RHY-1 was not identified as a member of 
lipid-binding protein family in C. elegans (64). However, the protein blast tool in NCBI 
revealed domains within RHY-1 that are similar to regions in many lipopolysaccharide (LPS) 
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modification proteins. LPS is a glycolipid in the outer membrane of Gram-negative bacteria, 
and LPS can trigger a variety of defense mechanisms in hosts. It has been reported that 
treatment of macrophages with LPS can activate HIF-1 activity and expression of hypoxia-
response genes (65). LPS also has been shown to induce ROS generation in human cell lines 
through the interaction of TOLL-like receptor TLR4 with NADP(H) oxidase Nox4 (66), and 
more intriguingly, Nox4 activity has been shown to be required for HIF-2alpha 
transcriptional activity in VHL-deficient renal cell line (67). In C. elegans, the MAPK 
signaling pathway, not the TOLL-like pathway which is involved in other species for LPS 
signaling, was reported for LPS-induced programmed cell death (68,69). It is possible that 
RHY-1 could participate LPS signaling pathways in C. elegans, such as MAPK pathway, 
and/or uncharacterized mechanisms involved in ROS generation, which also contribute on 
regulating HIF-1 activity. Another possibility is that RHY-1 could function to modify certain 
lipids to affect lipid metabolism. This is one of the proposed functions of the NRF-6/NRF-5 
pathway (48). This possibility is consistent with the serine point mutation discovered in the 
ia38 allele, which is conserved in this superfamily of proteins (Fig 3). This model is 
especially interesting because acyltransferase-mediated alteration of lipids in response to 
hypoxia has been reported in human cancerous cells. Goto et al. (70) showed that the 
synthesis of triglyceride and the presence of large lipid droplets increased significantly under 
hypoxia, and xanthohumol (XN), a diacylglycerol acyltransferase inhibitor, could 
significantly decrease the synthesis of triglyceride and cancel the formation of lipid drops. 
This study indicated that acyltransferase could function to convert the fatty acid to 
triglyceride in response to hypoxia. However, it is unclear whether or how this modification 
affect HIF-mediated signaling pathway. There are acyltransferase-3 proteins in human 
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(LOC390858) and mouse (LOC319888) with similarity with RHY-1. The biological 
functions of the proteins are unclear. Notably, Human LOC390858 cDNA was identified not 
only in normal tissues like brain, liver and prostate, but also germ cell tumor, liver tumor, and 
urinary bladder tumor, where HIF could highly expressed. Consistent with this, rhy-1 has 
been identified as a HIF-1 target gene in C. elegans. 
EGL-9 and RHY-1 both act in negative feedback loops to limit transcription of HIF-1 
target genes, but it is not yet clear whether these two proteins act in concert. As described 
above, EGL-9 might recruit transcriptional repressors to the HIF-1 complex. If this is true, 
then RHY-1 might control the localization of HIF-1, EGL-9, or putative repressors. Further 
studies will address these intriguing hypotheses, as they will ultimately inform our 
understanding of the regulatory circuits that control the hypoxia-inducible factor during 
development, homeostasis, and disease. 
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Figure Legends 
Figure 1: Nhr-57:GFP, a reporter of HIF-l-dependent transcription in hypoxia and in 
various mutant backgrounds, nhr-57:GFP expression in wild type and mutant animais, 
assayed by fluorescent microscopy (A - P) and by immunoblots (Q). A - P. For each 
experimental condition, representative fluorescent images are paired with Nomarski images 
of the same animal. With the exception of C, D., all animals were incubated in room air. A, 
B. wild type; C, D. wild type, incubated in 0.5% oxygen; E, F. vhl-1 (okl61)\ G, H. hif-1 
(ia04) vhl-1 (oklôl); I, J. egl-9 (sa307); K, L. egl-9 (sa307) hif-1 (ia04); M, N. rhy-1 
(okl402); O, P. rhy-1 (okl402) hif-1 (ia04). Q. nhr-57:GFP was assayed by immunoblot (20 
worms per lane): lane 1: wild type N2; lane 2: hif-1 (ia04); lane 3: vhl-1 (okl61)\ lane 4: rhy-
1 (okl402)\ lane 5: rhy-1 (okl402) hif-1 (ia04)\ lane 6: egl-9 (n571); lane 7: egl-9 (n586)\ 
lane 8: egl-9 (sa307)\ lane 9: egl-9 (sa307) hif-l(ia04); lane 10: egl-9 (sa307) rhy-1 (okl402)\ 
lane 11: egl-9 (sa307) vhl-1 (okl61)\ lane 12: rhy-1 (okl402) vhl-1 (oklôl). 
Figure 2: EGL-9 acts via VHL-1-dependent and VHL-1-independent pathways to 
regulate HIF-1. A. The levels of endogenous HIF-1 protein were assayed in wild type N2, 
vhl-l(oklôl), and egl-9(sa307) L4-stage animals. Asterisk refers to an unidentified protein 
that is recognized by the HIF-1 antibody, but is also present in hif-l(ia04) animals, which 
have a large deletion in the hif-1 gene. B. Real-time RT-PCR was used to quantitate mRNA 
levels in wild-type and mutant worms. The K10H10.2 and F22B5.4 genes are induced by 
hypoxia in a hif-1-dependent manner. The graph depicts average values from three 
independent experiments, and the error bars represent the mean standard error. 
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Figure 3: Rhy-1 gene and mutant alleles. A. Diagram representing the r/ry-i/W07A12.7 
genomic region. Exons are indicated by boxes. Arrows indicate the positions of the start 
codon ATG and the position of the ia38 S157F point mutation. The endpoints of the okl402 
and okl398 deletions are represented by brackets. B. The ia38 mutation is in a highly 
conserved region. RHY-1 is aligned with five other members of the gene family. Asterisks 
indicate amino acid identities. An arrow indicates that the position of the ia38 S157F point 
mutation. The NCBI reference numbers for the mammalian and bacterial sequences are: 
Unigene Hs.451560, Uni gene Mm.183576, and accession number Q6GIB3. The C. elegans 
genes rhy-1, W07A12.6, and nrf-6 are described at www.wormbase.org. 
Figure 4: RHY-1:GFP expression pattern. A. Structures of two reporters, in which GFP is 
fused to rhy-1 regulatory sequences. pSC09 includes the entire rhy-1 coding region and can 
rescue the rhy-1 ia38, okl402, and okl398 mutant phenotypes. Boxes indicate exons. B - C. 
Peri-nuclear expression pattern of the pSC09 reporter. An arrow indicates the position of a 
nucleus in a posterior intestine cell. D - E. Expression of the pSC15 reporter is strongly 
visible in the intestine and head sensory neurons in an adult hermaphrodite. 
Figure 5: RHY-1 has VHL-1-independent functions. A, B. Expression of two HIF-1 
target genes in various mutants. K10H10.2 and F22B5.4 mRNA levels were quantitated by 
real-time RT-PCR in three independent experiments. C. Relative levels of nhr-57:GFP as 
determined by immunoblots. D. hif-1 mRNA levels were assessed by real-time RT-PCR. 
Numbers indicate the relative mRNA levels compared with wild-type worms. The following 
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alleles were used for above studies: hif-1 (ia04); vhl-1 (oklôl); rhy-1 (okl402); egl-9 
(sa307). Error bars represent the mean standard error from 3 independent experiments. 
E. Protein blots probed with HIF-1 antisera. The position of HIF-1 is indicated. The protein 
loaded into the last 2 lanes is only one fifth the proteins loaded into the first 4 lanes. The 
relative expression levels of HIF-1 are indicated below each lane. These are average values 
from three independent experiments. The asterisk refers to an unidentified protein that is 
recognized by the HIF-1 antibody, but is also present in hifl(ia04) worms, which carry a 
large deletion in hif-1. 
Figure 6: The egl-9 mutant phenotype, as assayed by expression of HIF-1 target genes, 
is not increased in severity by additional mutants in vhl-1 or rhy-1. A. nhr-57\GFP 
protein levels assayed on immunoblots. Total protein from twenty L4-stage animals were 
loaded into each lane. B. Relative expression of the HIF-1 target genes K10H10.2 and 
F22B5.4, as determined by real-time RT-PCR. The following alleles were used in above 
studies: egl-9(sa307), rhy-l(okl402) and vhl-l(okl61 ). Averages from three independent 
repeats and mean standard error are shown. 
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CHAPTER 4 GENERAL CONCLUSIONS 
Summary 
In this dissertation, I used genome-wide cDNA microarrays, genetic strategies and 
molecular biological methods to analyze the function and regulation of the hypoxia-inducible 
factor HIF-1 in the nematode C. elegans. Major findings include: 1) Using genome-wide 
cDNA microarrays, I identified 110 hypoxia-regulated gene expression changes in the 
genetic model system C. elegans. These hypoxia-induced genes encode protein products with 
predicted functions mainly in signal transduction, metabolism, transporters/channels, 
extracellular matrix remodeling, transcription, and stress responses. 2) By comparing 
microarray data in wild-type worms and hif-1 loss-of-function worms, I showed that hif-1 
regulates the majority of hypoxia-induced gene expression changes. Functional studies 
showed that certain HIF-1 target genes, in particular gene phy-2, are critical for hypoxia 
survival. Microarray data also provided a clear evidence for the existence of hif-1 -
independent pathway(s) for hypoxia adaptation in C. elegans. 3) Using microarray data as the 
starting point, I generated a visual assay for HEF-1-dependent transcription. In forward and 
reverse genetic screens using this visual assay, I identified a new hif-1 allele, VHL-1-
independent functions for EGL-9, and a novel negative regulator of HIF-1, which we have 
named rhy-1. 4) I show that EGL-9 has functions regulating HIF-1 transcriptional activity, in 
addition to controlling HIF-1 protein stabilization in C. elegans. 5) I show that RHY-1, a 
novel membrane protein, negatively regulates HIF-1 activity by a feedback loop. RHY-1 
regulates HIF-1 via a VHL-1-independent mechanism, and my genetic data indicate that 
RHY-1 and EGL-9 could function in a common pathway. 
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Hypoxia-induced gene expression changes in C. elegans 
The transcriptional induction of gene expression is a major mechanism for organisms 
to adapt hypoxic conditions (1). Several studies have examined hypoxic-induces gene 
expression changes on a genome-wide scale in mammalian cell cultures and zebrafish (2-9). 
C. elegans has recently proven to be an important model system for studying hypoxia 
response (10,11). However, the knowledge of genes associated with hypoxia response in this 
model system is very limited. For my PhD project, I used cDNA microarrays containing 
17,817 predicted genes (94% of predicted genome), which are available at the Stuart Kim lab 
at Stanford University, to examine the differential gene expression in synchronized L3-stage 
wild-type (N2), hif-1 loss-of-function, and vhl-1 loss-of function worms under normoxic and 
hypoxic (0.1% O2) conditions, respectively. I identified 110 genes showing significantly 
different expression levels upon 4hours of exposure to hypoxia (Chapter 2 Table I & II). I 
confirmed some of these hypoxia-response genes by doing Northern blots (Chapter 2 Figure 
1). Among these 110 genes, 67 genes encode protein products having predicted functions in 
C. elegans, which mainly include functions in signal transduction, metabolism, 
transporters/channels, extracellular matrix remodeling, transcription, and stress responses 
(Chapter 2 Table I, Table II & Figure 6). Some of these protein products have conserved 
functions in mammals for hypoxia adaptation, such as metabolic enzymes for enhancing the 
anaerobic metabolism under hypoxia, calcium/calmodulin-dependent kinase EFK-1 for 
modulating protein synthesis under hypoxia (12), dioxygenase EGL-9 for negatively 
regulating hypoxia-inducible factor HIF in a feedback loop (13), prolyl 4-hydroxylase PHY-2 
for modulating collagen synthesis under hypoxia (14), and heatshock protein Hsp70 for 
regulating HIF stability in a VHL-independent mechanism (15). Notably, the hypoxia-
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response genes we identified greatly overlap with genes expressed during the dauer larvae 
stage & dauer formation (16). Consistent with this, I found that the forkhead transcription 
factor daf-16, which functions in the DAF-2 signaling pathway to induce dauer formation 
(17,18), was induced by hypoxia (Chapter 2, Figure 1C). I also found that hif-1 loss-of-
function mutants arrested as partial dauers at 27°C, and this is further evidence of the 
molecular links between hypoxia response and dauer formation in C. elegans. 
Critical roles of HIF-1 hypoxia-inducible factor during hypoxia response in C. elegans 
Hypoxia-inducible factor (HIF) is a well-defined master regulator of oxygen 
homeostasis, and it is conserved in mammals, worms, and flies (10,19,20). Compared to 
HIF's targets, there is limited knowledge of genes regulated by hypoxia via HIF-1 
independent mechanisms (21-23). Very few studies addressed the question of HIF-1 
dependent and independent gene expression (6,24,25), and the fraction of hypoxia regulated 
gene expression changes that are hif-1-dependent in living organisms remains largely 
unknown. Among 110 hypoxia-regulated genes I identified in C. elegans, 63 of them were 
not significantly regulated by hypoxia in hif-1 loss-of-function mutants (Chapter 2 Table I & 
Figure 1A), indicating that C. elegans HIF-1 functions as a major regulator for hypoxia 
response. This result is consistent with a recent microarray study showing that HIF-1 plays a 
major in the regulation of hypoxia-induced genes in mouse fibroblasts (25). My data also 
showed that mutation of vhl-1 abrogates most of these hif-1-dependent changes in mRNA 
expression (Chapter 2 Table I). There were also 47 genes that were significantly regulated by 
hypoxia in hif-1 loss-of-function mutants (Chapter 2 Table II & Figure IB), indicating that 
mechanisms of hypoxia signaling far beyond HIF-1. There are four major functional 
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categories for hif-1-dependent genes: signaling, metabolism, transporters/channels, and ECM 
remodeling (Chapter II Figure 6). There are also four major functional categories for hif-1-
independent genes: signaling, metabolism, transcription, and heat shock proteins (Chapter 2 
Figure 6). The high occurrence of genes involved in signaling and transcriptional regulation 
in hif-1-independent manner suggests the existance of other signaling pathways that may 
amplify or refine hypoxia responses. 
Our microarray data show that hif-1 is a key factor for the majority of gene 
expression change under the hypoxia conditions in C. elegans. To understand the functions 
of hif-1-dependent genes in hypoxia adaptation, I examined the in vivo requirement for 16 
HIF-1 target genes either using the existing mutants or using the RNA interference assay. I 
showed that 50% of examined genes have potential functions in hypoxia survival (Chapter 2 
Figure 3 & 5). In particular, I found that worms carrying a strong loss-of-mutation in the phy-
2 prolyl 4-hydroxylase alpha subunit exhibit dramatic hypoxia-dependent embryonic lethality, 
larval lethality and sterility (Chapter 2 Figure 3 & 5). phy-2 plays a central role in collagen 
synthesis, and is strongly expressed in worm hypodermis and spermatheca (Chapter 2 Figure 
4), indicating that collagen synthesis in the hypodermis and spermatheca is important to 
fertility and embryonic viability. 
A visual assay for studying HIF-1 transcriptional activity 
We are interested to study the regulatory mechanisms controlling HIF-1 activity, and 
an important goal was to employ the power of C. elegans genetics to isolate new regulators 
of HIF-1. To pursue this aim, I generated a visual assay system using microarray data as a 
starting point, as it provided a list of potential HIF-1 target genes (Chapter 2 Figure 1A). 
I l l  
Using a reporter construct in which the expression of green fluorescent protein (GFP) was 
controlled by regulatory sequences from one of HIF-1 target genes nhr-57 (Chapter 2 Figure 
1A), I generated transgenic worms, in which the HIF-1-dependent reporter was integrated 
into the genome by microparticle bombardment. Expression of the reporter is highly 
enhanced by hypoxia (Chapter 3 Figure 1C & D), and is over-expressed in vhl-1 loss-of 
function mutants in a hif-1-dependent manner (Chapter 3 Figure IE, F, G & H). Using this 
reporter, I isolated a new hif-1 allele ia07 (Chapter 4 Figure 1). I also determined that the 
reporter was expressed in egl-9 loss-of function worms at much greater level than in vhl-1 
loss-of-function worms (Chapter 3 Figure II, J, K & L). These data suggested VHL-1-
independent function(s) for EGL-9. egl-9 functions in a negative feedback loop. I used RNAi 
to test the hypothesis that other HIF-1 target genes might also be negative regulators of HIF-
1 function. I determined that inactivation of W07A12.7 (Chapter 2 Figure 1A) increased and 
expanded the reporter expression in a similar pattern to that exhibited by egl-9 mutants 
(Chapter 3 Figure 1M, N, O & P). We named this gene rhy-1 (regulator of hypoxia-inducible 
factor). Others in the lab used this visual assay system to isolate EMS induced mutants that 
increased HIF-1 activity. One of these mutations was rhy-1 allele. These data suggest that 
this visual assay system is effective for the identification of new hif-1 alleles and potential 
HIF-1 regulators. 
EGL-9 has a function independent of VHL-1 to regulate HIF-1 activity 
Previous studies proved that the HIF- 1/EGL-9/VHL-1 pathway is an evolutionary 
conserved mechanism for regulating HIF-1 protein stability (11). More recently, Bishop et al. 
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vhl-1 hif-1 hif-1 
(ok161) (ia07) (ia04) 
HIF-1 
NS 
Truncated HIF-1 
Figure 1. Protein blots probed with ceHIF-1 
antisera. The position of HIF-1 is indicated, which 
is overexpressed in vhl-1(ok161) mutants. A 
nonspecific band (NS) is also visible. A truncated 
HIF-1 is only present in hif-1(ia07) allele. 
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(26) described potential non-enzymatic functions of EGL-9. Specifically they showed that 
the egl-9 mutant phenotype was more severe than the vhl-1 mutant phenotype. Further, they 
showed that inhibitors of EGL-9 enzymatic activity caused phenotype similar to that seen in 
vhl-1 mutants. Consistent with the observation of Bishop et al, I observed tremendously 
enhanced expression of the nhr-57::GFP reporter in egl-9 mutant worms compared with vhl-1 
mutant worms (Chapter 3 Figure IE, F, I & J ). Also, using real-time RT-PCR, I showed that 
mRNA levels of two additional HIF-1 target genes were expressed at significantly higher 
levels in eg/-9-deficient worms than in vhl-1-deficient worms (Chapter 3 Figure 2B). To 
understand the potential mechanism by which EGL-9 regulates HIF-1 activity independent of 
VHL-1,1 quantitated the HIF-1 protein levels using Western blots. My data showed that HIF-
1 protein levels were at the similar levels in both vhl-1 (oklôl) and egl-9 (sa307) worms and 
were ~ 5-fold greater than in wild-type worms (Chapter 3 Figure 2A). This suggests that 
EGL-9 suppresses HIF-Ts transcriptional activity by an uncharacterized mechanism which is 
independent of the EGL-9/VHL-1 pathway. My observation is consistent with recently 
published studies showing that mammalian HLF prolyl hydroxylase (PHD2) might regulate 
HIF activity independent its function on HIF protein stability (27,28). 
Rhy-1 functions independent of VHL-1 to inhibit HIF-1 function 
I identified gene W07A12.7/r/ry-i as a novel negative regulator of HIF-1 from the 
RNAi screen, and others in the lab also discovered a rhy-1 allele in forward genetic screens. 
rhy-1 encodes a predicted multipass transmembrane protein that belongs to the 
acyltransferase-3 family, which contains a large number of genes with uncharacterized 
function in C. elegans. My molecular and genetic data suggest that RHY-1 regulates HIF-1 
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via a VHL-1-independent mechanism: 1) The HIF-1-dependent nhr-57::GFP reporter is 
expressed in distinct patterns and significantly different levels in rhy-1 -deficient worms and 
vhl-1-deficient worms (Chapter 3 Figure 1 E, F, M, N & Q); 2) Both hif-1 mRNA level and 
HIF-1 protein level are moderately increased -2-fold in rhy-1 loss-of-function mutant 
(Chapter 3 Figure 5E). Inactivation of vhl-1 causes much higher enhancement of HIF-1 
protein level (-5-fold) compared with inactivation of rhy-1 (Chapter 3 Figure 5E). However, 
the expression levels of the HIF-1-dependent reporter and HIF-1 target gene K10H10.2 are 
significantly higher in rhy-1 mutants than in vhl-1 mutants (Chapter 3 Figure 5A & C), 
indicating that RHY-1 could play an important role for regulating HIF-1 transactivation, 
rather than HIF-1 protein stabilization; 3) Worms that carry loss-of-function mutations for 
both rhy-1 and vhl-1 express significantly higher levels of HIF-1 target genes compared with 
each single loss-of-function mutant (Chapter 3 Figure 5A, B & C). This is evidence that the 
RHY-1-mediated pathway is different from the VHL-1-mediated pathway. 
My microarray studies revealed that W07A12.7/r/ry-i is a HIF-1 target gene (Chapter 
2 Table I and Figure 1A). Thus RHY-1 suppresses HIF-1 activity via a negative feedback 
loop. Studies in C. elegans have showed that NRF-6 functions for the antidepressant 
fluoxetine-induced nose contraction by a potential mechanism involved in transport and/or 
lipid metabolism (29,30). There are several acyltransferase-3 family proteins having high 
similarity with RHY-1, including C. elegans W07A12.6 and NRF-6, human LOC390858, 
mouse LOC319888 and S. aureus SAR0937 (Chapter 3 Figure 3B). Alignment with these 
proteins showed that the serine residue which is mutated in rhy-1 ia38 allele is highly 
conserved (Chapter 3 Figure 3B). This indicates that the serine residue could play an 
important role in a potential conserved function shared by these proteins. 
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EGL-9 and RHY-1 might function in the same pathway to regulate HIF-1 activity via 
a undefined VHL-1-independent mechanism. In this study, I did not observe that worms 
carrying loss-of-function mutations for both egl-9 and rhy-1 expressed higher levels of the 
HIF-1-dependent reporter and two HIF-1 target genes than each single mutant (Chapter 3 
Figure 6A & B). Studies in mammalian cells showed that EGL-9 homology EGLN1 was able 
to recruit a transcriptional repressor to inhibit HIF-1 (27). The clear peri-nuclear expression 
pattern of RHY-1 (Chapter 3 Figure 4B & C) combined with proposed functions of NRF-6 
on transport and/or lipid metabolism suggest that RHY-1 might function to transport or 
modify signaling molecules such as lipids, which might regulate the formation of an EGL-
9/HIF-l repressor complex. 
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